{ "version": "2.2", "instance": { "pmi20260519_s1.htm": { "nsprefix": "pmi", "nsuri": "http://picardmedical.com/20260331", "dts": { "schema": { "local": [ "pmi-20260331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd", "https://xbrl.sec.gov/country/2026/country-2026.xsd", "https://xbrl.sec.gov/currency/2026/currency-2026.xsd", "https://xbrl.sec.gov/dei/2026/dei-2026.xsd", "https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd", "https://xbrl.sec.gov/exch/2026/exch-2026.xsd", "https://xbrl.sec.gov/naics/2026/naics-2026.xsd", "https://xbrl.sec.gov/sic/2026/sic-2026.xsd", "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd" ] }, "calculationLink": { "local": [ "pmi-20260331_cal.xml" ] }, "definitionLink": { "local": [ "pmi-20260331_def.xml" ] }, "labelLink": { "local": [ "pmi-20260331_lab.xml" ] }, "presentationLink": { "local": [ "pmi-20260331_pre.xml" ] }, "inline": { "local": [ "pmi20260519_s1.htm" ] } }, "keyStandard": 375, "keyCustom": 107, "axisStandard": 37, "axisCustom": 0, "memberStandard": 54, "memberCustom": 87, "hidden": { "total": 117, "http://fasb.org/us-gaap/2026": 103, "http://picardmedical.com/20260331": 11, "http://xbrl.sec.gov/dei/2026": 3 }, "contextCount": 531, "entityCount": 1, "segmentCount": 143, "elementCount": 828, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2026": 1728, "http://xbrl.sec.gov/dei/2026": 16 }, "report": { "R1": { "role": "http://picardmedical.com/20260331/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true } }, "R2": { "role": "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "longName": "001 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:ConvertibleNotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R3": { "role": "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets-parentheticals", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "i_2021-09-30", "name": "us-gaap:TemporaryEquitySharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R5": { "role": "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "longName": "004 - Statement - Consolidated Statements of Changes in Temporary Equity and Stockholders' Equity (Deficit)", "shortName": "Consolidated Statements of Changes in Temporary Equity and Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "i_2023-12-31_StatementEquityComponentsAxis-PreferredStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31_StatementEquityComponentsAxis-PreferredStockMember", "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R6": { "role": "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R7": { "role": "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets", "longName": "006 - Statement - Unaudited Condensed Consolidated Balance Sheets", "shortName": "Unaudited Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true } }, "R8": { "role": "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals", "longName": "007 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Unaudited Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "i_2021-09-30", "name": "us-gaap:TemporaryEquitySharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss", "longName": "008 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R10": { "role": "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "longName": "009 - Statement - Unaudited Consolidated Statements of Changes in Temporary Equity and Stockholders' Equity (Deficit)", "shortName": "Unaudited Consolidated Statements of Changes in Temporary Equity and Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Statements", "order": "10", "firstAnchor": { "contextRef": "i_2023-12-31_StatementEquityComponentsAxis-PreferredStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31_DebtConversionByUniqueDescriptionAxis-ConversionOfDebtIntoCommonStockMember_StatementEquityComponentsAxis-PreferredStockMember", "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R11": { "role": "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows", "longName": "010 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows", "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Statements", "order": "11", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R12": { "role": "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan", "longName": "011 - Disclosure - Note 1 - Description of Business, Basis of Presentation and Management's Plan", "shortName": "Note 1 - Description of Business, Basis of Presentation and Management's Plan", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R13": { "role": "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "012 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R14": { "role": "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments", "longName": "013 - Disclosure - Note 3 - Fair Value of Financial Instruments", "shortName": "Note 3 - Fair Value of Financial Instruments", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R15": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components", "longName": "014 - Disclosure - Note 4 - Certain Balance Sheet Components", "shortName": "Note 4 - Certain Balance Sheet Components", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R16": { "role": "http://picardmedical.com/20260331/role/statement-note-5-revenue", "longName": "015 - Disclosure - Note 5 - Revenue", "shortName": "Note 5 - Revenue", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R17": { "role": "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "longName": "016 - Disclosure - Note 6 - Concentrations", "shortName": "Note 6 - Concentrations", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R18": { "role": "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "longName": "017 - Disclosure - Note 7 - Commitments and Contingencies", "shortName": "Note 7 - Commitments and Contingencies", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R19": { "role": "http://picardmedical.com/20260331/role/statement-note-8-debt", "longName": "018 - Disclosure - Note 8 - Debt", "shortName": "Note 8 - Debt", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "longName": "019 - Disclosure - Note 9 - Temporary Equity and Stockholders' Equity (Deficit)", "shortName": "Note 9 - Temporary Equity and Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R21": { "role": "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation", "longName": "020 - Disclosure - Note 10 - Share Based Compensation", "shortName": "Note 10 - Share Based Compensation", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://picardmedical.com/20260331/role/statement-note-11-income-taxes", "longName": "021 - Disclosure - Note 11 - Income Taxes", "shortName": "Note 11 - Income Taxes", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share", "longName": "022 - Disclosure - Note 12 - Net Loss Per Share", "shortName": "Note 12 - Net Loss Per Share", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans", "longName": "023 - Disclosure - Note 13 - Retirement Plans", "shortName": "Note 13 - Retirement Plans", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "longName": "024 - Disclosure - Note 14 - Related Party Transactions", "shortName": "Note 14 - Related Party Transactions", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R26": { "role": "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "longName": "025 - Disclosure - Note 15 - Subsequent Events", "shortName": "Note 15 - Subsequent Events", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q", "longName": "026 - Disclosure - Note 1 - Description of Business, Basis of Presentation and Management's Plan -10-Q", "shortName": "Note 1 - Description of Business, Basis of Presentation and Management's Plan -10-Q", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R28": { "role": "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q", "longName": "027 - Disclosure - Note 2 - Summary of Significant Accounting Policies -10-Q", "shortName": "Note 2 - Summary of Significant Accounting Policies -10-Q", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R29": { "role": "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q", "longName": "028 - Disclosure - Note 3 - Fair Value of Financial Instruments -10-Q", "shortName": "Note 3 - Fair Value of Financial Instruments -10-Q", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q", "longName": "029 - Disclosure - Note 4 - Certain Balance Sheet Components -10-Q", "shortName": "Note 4 - Certain Balance Sheet Components -10-Q", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "longName": "030 - Disclosure - Note 5 - Revenue -10-Q", "shortName": "Note 5 - Revenue -10-Q", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "longName": "031 - Disclosure - Note 6 - Concentrations -10-Q", "shortName": "Note 6 - Concentrations -10-Q", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "longName": "032 - Disclosure - Note 7 - Commitments and Contingencies -10-Q", "shortName": "Note 7 - Commitments and Contingencies -10-Q", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "longName": "033 - Disclosure - Note 8 - Debt -10-Q", "shortName": "Note 8 - Debt -10-Q", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R35": { "role": "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "longName": "034 - Disclosure - Note 9 - Temporary Equity and Stockholders' Deficit -10-Q", "shortName": "Note 9 - Temporary Equity and Stockholders' Deficit -10-Q", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q", "longName": "035 - Disclosure - Note 10 - Share Based Compensation -10-Q", "shortName": "Note 10 - Share Based Compensation -10-Q", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "36", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R37": { "role": "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-10q", "longName": "036 - Disclosure - Note 11 - Income Taxes -10-Q", "shortName": "Note 11 - Income Taxes -10-Q", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "37", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R38": { "role": "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-10q", "longName": "037 - Disclosure - Note 12 - Net Loss Per Share -10-Q", "shortName": "Note 12 - Net Loss Per Share -10-Q", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "38", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R39": { "role": "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q", "longName": "038 - Disclosure - Note 13 - Retirement Plans -10-Q", "shortName": "Note 13 - Retirement Plans -10-Q", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "39", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R40": { "role": "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q", "longName": "039 - Disclosure - Note 14 - Related Party Transactions -10-Q", "shortName": "Note 14 - Related Party Transactions -10-Q", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "40", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "longName": "040 - Disclosure - Note 15 - Subsequent Events - 10-Q", "shortName": "Note 15 - Subsequent Events - 10-Q", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Notes", "order": "41", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies", "longName": "041 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "policies", "menuCat": "Policies", "order": "42", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true } }, "R43": { "role": "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-tables", "longName": "042 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "pmi:SummaryOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R44": { "role": "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-tables", "longName": "043 - Disclosure - Note 3 - Fair Value of Financial Instruments (Tables)", "shortName": "Note 3 - Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R45": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-tables", "longName": "044 - Disclosure - Note 4 - Certain Balance Sheet Components (Tables)", "shortName": "Note 4 - Certain Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R46": { "role": "http://picardmedical.com/20260331/role/statement-note-5-revenue-tables", "longName": "045 - Disclosure - Note 5 - Revenue (Tables)", "shortName": "Note 5 - Revenue (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R47": { "role": "http://picardmedical.com/20260331/role/statement-note-6-concentrations-tables", "longName": "046 - Disclosure - Note 6 - Concentrations (Tables)", "shortName": "Note 6 - Concentrations (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R48": { "role": "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-tables", "longName": "047 - Disclosure - Note 7 - Commitments and Contingencies (Tables)", "shortName": "Note 7 - Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "pmi:SummaryOfFinanceAndOperatingRightofuseAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://picardmedical.com/20260331/role/statement-note-8-debt-tables", "longName": "048 - Disclosure - Note 8 - Debt (Tables)", "shortName": "Note 8 - Debt (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true } }, "R50": { "role": "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-tables", "longName": "049 - Disclosure - Note 9 - Temporary Equity and Stockholders' Equity (Deficit) (Tables)", "shortName": "Note 9 - Temporary Equity and Stockholders' Equity (Deficit) (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "pmi:SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R51": { "role": "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-tables", "longName": "050 - Disclosure - Note 10 - Share Based Compensation (Tables)", "shortName": "Note 10 - Share Based Compensation (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R52": { "role": "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-tables", "longName": "051 - Disclosure - Note 11 - Income Taxes (Tables)", "shortName": "Note 11 - Income Taxes (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true } }, "R53": { "role": "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-tables", "longName": "052 - Disclosure - Note 12 - Net Loss Per Share (Tables)", "shortName": "Note 12 - Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R54": { "role": "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-tables", "longName": "053 - Disclosure - Note 2 - Summary of Significant Accounting Policies -10-Q (Tables)", "shortName": "Note 2 - Summary of Significant Accounting Policies -10-Q (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "pmi:SummaryOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R55": { "role": "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-tables", "longName": "054 - Disclosure - Note 3 - Fair Value of Financial Instruments -10-Q (Tables)", "shortName": "Note 3 - Fair Value of Financial Instruments -10-Q (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R56": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-tables", "longName": "055 - Disclosure - Note 4 - Certain Balance Sheet Components -10-Q (Tables)", "shortName": "Note 4 - Certain Balance Sheet Components -10-Q (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "56", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R57": { "role": "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-tables", "longName": "056 - Disclosure - Note 5 - Revenue -10-Q (Tables)", "shortName": "Note 5 - Revenue -10-Q (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "57", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R58": { "role": "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-tables", "longName": "057 - Disclosure - Note 6 - Concentrations -10-Q (Tables)", "shortName": "Note 6 - Concentrations -10-Q (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "58", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R59": { "role": "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-tables", "longName": "058 - Disclosure - Note 7 - Commitments and Contingencies -10-Q (Tables)", "shortName": "Note 7 - Commitments and Contingencies -10-Q (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "59", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "pmi:SummaryOfFinanceAndOperatingRightofuseAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R60": { "role": "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-tables", "longName": "059 - Disclosure - Note 9 - Temporary Equity and Stockholders' Deficit -10-Q (Tables)", "shortName": "Note 9 - Temporary Equity and Stockholders' Deficit -10-Q (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "60", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "pmi:SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R61": { "role": "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-tables", "longName": "060 - Disclosure - Note 10 - Share Based Compensation -10-Q (Tables)", "shortName": "Note 10 - Share Based Compensation -10-Q (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "61", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R62": { "role": "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-10q-tables", "longName": "061 - Disclosure - Note 12 - Net Loss Per Share -10-Q (Tables)", "shortName": "Note 12 - Net Loss Per Share -10-Q (Tables)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "tables", "menuCat": "Tables", "order": "62", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R63": { "role": "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-details-textual", "longName": "062 - Disclosure - Note 1 - Description of Business, Basis of Presentation and Management's Plan (Details Textual)", "shortName": "Note 1 - Description of Business, Basis of Presentation and Management's Plan (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "d_2025-07-11_2025-07-11", "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-07-11_2025-07-11_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember", "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R64": { "role": "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "longName": "063 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R65": { "role": "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details", "longName": "064 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Useful Lives of Property and Equipment (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Useful Lives of Property and Equipment (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "i_2026-03-31_PropertyPlantAndEquipmentByTypeAxis-TahdriverEquipmentMember_RangeAxis-MinimumMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "pmi:SummaryOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R66": { "role": "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details", "longName": "065 - Disclosure - Note 3 - Fair Value of Financial Instruments - Summary of Fair Value Measurements (Details)", "shortName": "Note 3 - Fair Value of Financial Instruments - Summary of Fair Value Measurements (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "i_2026-03-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31_FairValueByLiabilityClassAxis-DerivativeFinancialInstrumentsLiabilitiesMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "us-gaap:DerivativeLiabilities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R67": { "role": "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details-parentheticals", "longName": "066 - Disclosure - Note 3 - Fair Value of Financial Instruments - Summary of Fair Value Measurements (Details) (Parentheticals)", "shortName": "Note 3 - Fair Value of Financial Instruments - Summary of Fair Value Measurements (Details) (Parentheticals)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "parenthetical", "menuCat": "Details", "order": "67", "firstAnchor": null, "uniqueAnchor": null }, "R68": { "role": "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details", "longName": "067 - Disclosure - Note 3 - Fair Value of Financial Instruments - Valuation Measurements (Details)", "shortName": "Note 3 - Fair Value of Financial Instruments - Valuation Measurements (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "i_2025-12-31_DerivativeInstrumentRiskAxis-SeniorSecuredNoteMember_MeasurementInputTypeAxis-MeasurementInputCalibrationDiscountMember", "name": "us-gaap:DerivativeLiabilityMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31_DerivativeInstrumentRiskAxis-EmbeddedDerivativeFinancialInstrumentsMember_RangeAxis-MinimumMember", "name": "pmi:ProbabilitySuccessfulFinancingOrIpoPercent", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R69": { "role": "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details", "longName": "068 - Disclosure - Note 3 - Fair Value of Financial Instruments - Fair Values of Derivative Liabilities (Details)", "shortName": "Note 3 - Fair Value of Financial Instruments - Fair Values of Derivative Liabilities (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "i_2025-12-31_DerivativeInstrumentRiskAxis-EmbeddedDerivativeFinancialInstrumentsMember", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_DerivativeInstrumentRiskAxis-EmbeddedDerivativeFinancialInstrumentsMember", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R70": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual", "longName": "069 - Disclosure - Note 4 - Certain Balance Sheet Components (Details Textual)", "shortName": "Note 4 - Certain Balance Sheet Components (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisposals", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R71": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details", "longName": "070 - Disclosure - Note 4 - Certain Balance Sheet Components - Summary of Inventory (Details)", "shortName": "Note 4 - Certain Balance Sheet Components - Summary of Inventory (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R72": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details", "longName": "071 - Disclosure - Note 4 - Certain Balance Sheet Components - Summary of Property and Equipment (Details)", "shortName": "Note 4 - Certain Balance Sheet Components - Summary of Property and Equipment (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R73": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-details", "longName": "072 - Disclosure - Note 4 - Certain Balance Sheet Components - Summary of Intangible Assets (Details)", "shortName": "Note 4 - Certain Balance Sheet Components - Summary of Intangible Assets (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R74": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details", "longName": "073 - Disclosure - Note 4 - Certain Balance Sheet Components - Estimated Future Amortization Expenses (Details)", "shortName": "Note 4 - Certain Balance Sheet Components - Estimated Future Amortization Expenses (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R75": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details", "longName": "074 - Disclosure - Note 4 - Certain Balance Sheet Components - Summary of Other Accrued Liabilities (Details)", "shortName": "Note 4 - Certain Balance Sheet Components - Summary of Other Accrued Liabilities (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:OtherAccruedLiabilitiesNoncurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R76": { "role": "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "longName": "075 - Disclosure - Note 5 - Revenue (Details Textual)", "shortName": "Note 5 - Revenue (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-GeographicConcentrationRiskMember_StatementGeographicalAxis-CA", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R77": { "role": "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "longName": "076 - Disclosure - Note 5 - Revenue - Disaggregation of Revenue (Details)", "shortName": "Note 5 - Revenue - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R78": { "role": "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual", "longName": "077 - Disclosure - Note 6 - Concentrations (Details Textual)", "shortName": "Note 6 - Concentrations (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerEMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R79": { "role": "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details", "longName": "078 - Disclosure - Note 6 - Concentrations - Summary of Concentration Risks (Details)", "shortName": "Note 6 - Concentrations - Summary of Concentration Risks (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R80": { "role": "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-details", "longName": "079 - Disclosure - Note 6 - Concentrations - Summary of Long-lived Assets by Area (Details)", "shortName": "Note 6 - Concentrations - Summary of Long-lived Assets by Area (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R81": { "role": "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual", "longName": "080 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual)", "shortName": "Note 7 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31_CounterpartyNameAxis-SyncardiaMedicalBeijingMember_OwnershipAxis-NoncontrollingOwnersMember", "name": "us-gaap:InventoryNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R82": { "role": "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-details", "longName": "081 - Disclosure - Note 7 - Commitments and Contingencies - Summary of Right-of-Use Assets (Details)", "shortName": "Note 7 - Commitments and Contingencies - Summary of Right-of-Use Assets (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R83": { "role": "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details", "longName": "082 - Disclosure - Note 7 - Commitments and Contingencies - Summary of Lease Payment Obligations (Details)", "shortName": "Note 7 - Commitments and Contingencies - Summary of Lease Payment Obligations (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "pmi:SummaryOfFutureMinimumOperatingAndFinanceLeasePaymentsTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "pmi:SummaryOfFutureMinimumOperatingAndFinanceLeasePaymentsTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R84": { "role": "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-details", "longName": "083 - Disclosure - Note 7 - Commitments and Contingencies - Summary of Lease Costs (Details)", "shortName": "Note 7 - Commitments and Contingencies - Summary of Lease Costs (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R85": { "role": "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "longName": "084 - Disclosure - Note 8 - Debt (Details Textual)", "shortName": "Note 8 - Debt (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ProceedsFromIssuanceOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-09-02_2025-09-02_DebtConversionByUniqueDescriptionAxis-ConversionOfTheAnotherDimensionNoteToCommonStockMember", "name": "us-gaap:DebtConversionOriginalDebtAmount1", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R86": { "role": "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details", "longName": "085 - Disclosure - Note 8 - Debt - Summary of Convertible Note Balances (Details)", "shortName": "Note 8 - Debt - Summary of Convertible Note Balances (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true } }, "R87": { "role": "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual", "longName": "086 - Disclosure - Note 9 - Temporary Equity and Stockholders' Equity (Deficit) (Details Textual)", "shortName": "Note 9 - Temporary Equity and Stockholders' Equity (Deficit) (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "i_2021-09-30", "name": "us-gaap:TemporaryEquitySharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2022-12-01_2022-12-31", "name": "pmi:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R88": { "role": "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-reserved-common-stock-details", "longName": "087 - Disclosure - Note 9 - Temporary Equity and Stockholders' Equity (Deficit) - Reserved Common Stock (Details)", "shortName": "Note 9 - Temporary Equity and Stockholders' Equity (Deficit) - Reserved Common Stock (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "pmi:SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31_StatementClassOfStockAxis-CommonStockIssuedFromConvertibleNotesMember", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "pmi:SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R89": { "role": "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual", "longName": "088 - Disclosure - Note 10 - Share Based Compensation (Details Textual)", "shortName": "Note 10 - Share Based Compensation (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R90": { "role": "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details", "longName": "089 - Disclosure - Note 10 - Share Based Compensation - Summary of Stock Option Transactions (Details)", "shortName": "Note 10 - Share Based Compensation - Summary of Stock Option Transactions (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "d_2025-09-29_2025-09-29", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31_AwardTypeAxis-EmployeeStockOptionMember", "name": "pmi:SharebasedCompensationArrangementBySharebasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R91": { "role": "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-valuation-assumptions-details", "longName": "090 - Disclosure - Note 10 - Share Based Compensation - Summary of Valuation Assumptions (Details)", "shortName": "Note 10 - Share Based Compensation - Summary of Valuation Assumptions (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "d_2026-02-01_2026-03-31_AwardTypeAxis-EmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-05-30_2025-05-30_AwardTypeAxis-EmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R92": { "role": "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-details", "longName": "091 - Disclosure - Note 10 - Share Based Compensation - Allocation of Stock-based Compensation Expense (Details)", "shortName": "Note 10 - Share Based Compensation - Allocation of Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31_IncomeStatementLocationAxis-CostOfSalesMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R93": { "role": "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual", "longName": "092 - Disclosure - Note 11 - Income Taxes (Details Textual)", "shortName": "Note 11 - Income Taxes (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R94": { "role": "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-and-income-loss-before-income-taxes-details", "longName": "093 - Disclosure - Note 11 - Income Taxes - Components and Income (Loss) Before Income Taxes (Details)", "shortName": "Note 11 - Income Taxes - Components and Income (Loss) Before Income Taxes (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true } }, "R95": { "role": "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details", "longName": "094 - Disclosure - Note 11 - Income Taxes - Schedule of Components for Income Taxes (Details)", "shortName": "Note 11 - Income Taxes - Schedule of Components for Income Taxes (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true } }, "R96": { "role": "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details", "longName": "095 - Disclosure - Note 11 - Income Taxes - Reconciliation of Benefits for Income Taxes (Details)", "shortName": "Note 11 - Income Taxes - Reconciliation of Benefits for Income Taxes (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true } }, "R97": { "role": "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details", "longName": "096 - Disclosure - Note 11 - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)", "shortName": "Note 11 - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true } }, "R98": { "role": "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details", "longName": "097 - Disclosure - Note 11 - Income Taxes - Income Taxes Paid By Jurisdiction (Details)", "shortName": "Note 11 - Income Taxes - Income Taxes Paid By Jurisdiction (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeTaxPaidFederalAfterRefundReceived", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "pmi:ScheduleOfIncomeTaxesPaidTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:IncomeTaxPaidFederalAfterRefundReceived", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "pmi:ScheduleOfIncomeTaxesPaidTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true } }, "R99": { "role": "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details", "longName": "098 - Disclosure - Note 12 - Net Loss Per Share - Antidilutive Securities (Details)", "shortName": "Note 12 - Net Loss Per Share - Antidilutive Securities (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R100": { "role": "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-details-textual", "longName": "099 - Disclosure - Note 13 - Retirement Plans (Details Textual)", "shortName": "Note 13 - Retirement Plans (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31_RetirementPlanNameAxis-Company401kPlanMember", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R101": { "role": "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "longName": "100 - Disclosure - Note 14 - Related Party Transactions (Details Textual)", "shortName": "Note 14 - Related Party Transactions (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "i_2025-12-31", "name": "us-gaap:NotesReceivableGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2024-12-31", "name": "us-gaap:NotesReceivableGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R102": { "role": "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "longName": "101 - Disclosure - Note 15 - Subsequent Events (Details Textual)", "shortName": "Note 15 - Subsequent Events (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:InterestPaidNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2025-09-30_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-RelatedPartyNoteReceivableMember", "name": "us-gaap:NotesReceivableNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R103": { "role": "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q-details-textual", "longName": "102 - Disclosure - Note 1 - Description of Business, Basis of Presentation and Management's Plan -10-Q (Details Textual)", "shortName": "Note 1 - Description of Business, Basis of Presentation and Management's Plan -10-Q (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ProceedsFromIssuanceOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31_RelatedPartyTransactionsByRelatedPartyAxis-RelatedPartyMember", "name": "us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R104": { "role": "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-details-textual", "longName": "103 - Disclosure - Note 2 - Summary of Significant Accounting Policies -10-Q (Details Textual)", "shortName": "Note 2 - Summary of Significant Accounting Policies -10-Q (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R105": { "role": "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "longName": "104 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Useful Lives of Property and Equipment -10-Q (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Useful Lives of Property and Equipment -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "i_2026-03-31_PropertyPlantAndEquipmentByTypeAxis-TahdriverEquipmentMember_RangeAxis-MinimumMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "tbody", "table", "pmi:SummaryOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R106": { "role": "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-details-textual", "longName": "105 - Disclosure - Note 3 - Fair Value of Financial Instruments -10-Q (Details Textual)", "shortName": "Note 3 - Fair Value of Financial Instruments -10-Q (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RepaymentsOfConvertibleDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R107": { "role": "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "longName": "106 - Disclosure - Note 3 - Fair Value of Financial Instruments - Summary of Fair Value Measurements -10-Q (Details)", "shortName": "Note 3 - Fair Value of Financial Instruments - Summary of Fair Value Measurements -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "i_2026-03-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R108": { "role": "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details-parentheticals", "longName": "107 - Disclosure - Note 3 - Fair Value of Financial Instruments - Summary of Fair Value Measurements -10-Q (Details) (Parentheticals)", "shortName": "Note 3 - Fair Value of Financial Instruments - Summary of Fair Value Measurements -10-Q (Details) (Parentheticals)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "parenthetical", "menuCat": "Details", "order": "108", "firstAnchor": null, "uniqueAnchor": null }, "R109": { "role": "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "longName": "108 - Disclosure - Note 3 - Fair Value of Financial Instruments - Valuation Measurements -10-Q (Details)", "shortName": "Note 3 - Fair Value of Financial Instruments - Valuation Measurements -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "i_2026-03-31_DerivativeInstrumentRiskAxis-SeniorSecuredNoteMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember_RangeAxis-MinimumMember", "name": "us-gaap:DerivativeLiabilityMeasurementInput", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R110": { "role": "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details", "longName": "109 - Disclosure - Note 3 - Fair Value of Financial Instruments - Fair Values of Derivative Liabilities -10-Q (Details)", "shortName": "Note 3 - Fair Value of Financial Instruments - Fair Values of Derivative Liabilities -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "i_2025-12-31_DerivativeInstrumentRiskAxis-SeniorSecuredNoteMember", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31_DerivativeInstrumentRiskAxis-SeniorSecuredNoteMember", "name": "pmi:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossOnSettlements", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R111": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "longName": "110 - Disclosure - Note 4 - Certain Balance Sheet Components -10-Q (Details Textual)", "shortName": "Note 4 - Certain Balance Sheet Components -10-Q (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:CostOfGoodsAndServicesSoldAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R112": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details", "longName": "111 - Disclosure - Note 4 - Certain Balance Sheet Components - Summary of Inventory -10-Q (Details)", "shortName": "Note 4 - Certain Balance Sheet Components - Summary of Inventory -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R113": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details", "longName": "112 - Disclosure - Note 4 - Certain Balance Sheet Components - Summary of Property and Equipment -10-Q (Details)", "shortName": "Note 4 - Certain Balance Sheet Components - Summary of Property and Equipment -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R114": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-10q-details", "longName": "113 - Disclosure - Note 4 - Certain Balance Sheet Components - Summary of Intangible Assets -10-Q (Details)", "shortName": "Note 4 - Certain Balance Sheet Components - Summary of Intangible Assets -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R115": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details", "longName": "114 - Disclosure - Note 4 - Certain Balance Sheet Components - Estimated Future Amortization Expenses -10-Q (Details)", "shortName": "Note 4 - Certain Balance Sheet Components - Estimated Future Amortization Expenses -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true } }, "R116": { "role": "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details", "longName": "115 - Disclosure - Note 4 - Certain Balance Sheet Components - Summary of Other Accrued Liabilities -10-Q (Details)", "shortName": "Note 4 - Certain Balance Sheet Components - Summary of Other Accrued Liabilities -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R117": { "role": "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "longName": "116 - Disclosure - Note 5 - Revenue -10-Q (Details Textual)", "shortName": "Note 5 - Revenue -10-Q (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R118": { "role": "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "longName": "117 - Disclosure - Note 5 - Revenue - Disaggregation of Revenue -10-Q (Details)", "shortName": "Note 5 - Revenue - Disaggregation of Revenue -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R119": { "role": "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "longName": "118 - Disclosure - Note 6 - Concentrations -10-Q (Details Textual)", "shortName": "Note 6 - Concentrations -10-Q (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "i_2026-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember", "name": "us-gaap:AccountsReceivableNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2026-03-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember", "name": "us-gaap:AccountsReceivableNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true } }, "R120": { "role": "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "longName": "119 - Disclosure - Note 6 - Concentrations - Summary of Concentration Risks -10-Q (Details)", "shortName": "Note 6 - Concentrations - Summary of Concentration Risks -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerCMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R121": { "role": "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-10q-details", "longName": "120 - Disclosure - Note 6 - Concentrations - Summary of Long-lived Assets by Area -10-Q (Details)", "shortName": "Note 6 - Concentrations - Summary of Long-lived Assets by Area -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:PropertyPlantAndEquipmentNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R122": { "role": "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "longName": "121 - Disclosure - Note 7 - Commitments and Contingencies -10-Q (Details Textual)", "shortName": "Note 7 - Commitments and Contingencies -10-Q (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "122", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R123": { "role": "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-10q-details", "longName": "122 - Disclosure - Note 7 - Commitments and Contingencies - Summary of Right-of-Use Assets -10-Q (Details)", "shortName": "Note 7 - Commitments and Contingencies - Summary of Right-of-Use Assets -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "123", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R124": { "role": "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "longName": "123 - Disclosure - Note 7 - Commitments and Contingencies - Summary of Lease Payment Obligations -10-Q (Details)", "shortName": "Note 7 - Commitments and Contingencies - Summary of Lease Payment Obligations -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "124", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "p", "td", "tr", "tbody", "table", "pmi:SummaryOfFutureMinimumOperatingAndFinanceLeasePaymentsTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "p", "td", "tr", "tbody", "table", "pmi:SummaryOfFutureMinimumOperatingAndFinanceLeasePaymentsTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true, "unique": true } }, "R125": { "role": "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-10q-details", "longName": "124 - Disclosure - Note 7 - Commitments and Contingencies - Summary of Lease Costs -10-Q (Details)", "shortName": "Note 7 - Commitments and Contingencies - Summary of Lease Costs -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "125", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R126": { "role": "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "longName": "125 - Disclosure - Note 8 - Debt -10-Q (Details Textual)", "shortName": "Note 8 - Debt -10-Q (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "126", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ProceedsFromIssuanceOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31_DebtInstrumentAxis-The2025SeniorSecuredNoteMember", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R127": { "role": "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "longName": "126 - Disclosure - Note 9 - Temporary Equity and Stockholders' Deficit -10-Q (Details Textual)", "shortName": "Note 9 - Temporary Equity and Stockholders' Deficit -10-Q (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "127", "firstAnchor": { "contextRef": "i_2021-09-30", "name": "us-gaap:TemporaryEquitySharesAuthorized", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-02-01_2026-03-31", "name": "us-gaap:ProceedsFromStockOptionsExercised", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R128": { "role": "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-reserved-common-stock-10q-details", "longName": "127 - Disclosure - Note 9 - Temporary Equity and Stockholders' Deficit - Reserved Common Stock -10-Q (Details)", "shortName": "Note 9 - Temporary Equity and Stockholders' Deficit - Reserved Common Stock -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "128", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "pmi:SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R129": { "role": "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "longName": "128 - Disclosure - Note 10 - Share Based Compensation -10-Q (Details Textual)", "shortName": "Note 10 - Share Based Compensation -10-Q (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "129", "firstAnchor": { "contextRef": "i_2026-03-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R130": { "role": "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "longName": "129 - Disclosure - Note 10 - Share Based Compensation - Summary of Stock Option Transactions -10-Q (Details)", "shortName": "Note 10 - Share Based Compensation - Summary of Stock Option Transactions -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "130", "firstAnchor": { "contextRef": "d_2025-09-29_2025-09-29", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31_AwardTypeAxis-EmployeeStockOptionMember", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R131": { "role": "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details", "longName": "130 - Disclosure - Note 10 - Share Based Compensation - Valuation Assumptions -10-Q (Details)", "shortName": "Note 10 - Share Based Compensation - Valuation Assumptions -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "131", "firstAnchor": { "contextRef": "d_2026-02-01_2026-03-31_AwardTypeAxis-EmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-02-01_2026-03-31_AwardTypeAxis-EmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R132": { "role": "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-10q-details", "longName": "131 - Disclosure - Note 10 - Share Based Compensation - Allocation of Stock-based Compensation Expense -10-Q (Details)", "shortName": "Note 10 - Share Based Compensation - Allocation of Stock-based Compensation Expense -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "132", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-01-01_2026-03-31_NatureOfExpenseAxis-CostOfRevenueMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } }, "R133": { "role": "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-10q-details", "longName": "132 - Disclosure - Note 12 - Net Loss Per Share - Antidilutive Securities -10-Q (Details)", "shortName": "Note 12 - Net Loss Per Share - Antidilutive Securities -10-Q (Details)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "133", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R134": { "role": "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q-details-textual", "longName": "133 - Disclosure - Note 13 - Retirement Plans -10-Q (Details Textual)", "shortName": "Note 13 - Retirement Plans -10-Q (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "134", "firstAnchor": { "contextRef": "d_2026-01-01_2026-03-31_RetirementPlanNameAxis-Company401kPlanMember", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R135": { "role": "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q-details-textual", "longName": "134 - Disclosure - Note 14 - Related Party Transactions -10-Q (Details Textual)", "shortName": "Note 14 - Related Party Transactions -10-Q (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "135", "firstAnchor": { "contextRef": "i_2024-06-25_DebtInstrumentAxis-FangFamilyFundIiLoanMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": null }, "R136": { "role": "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "longName": "135 - Disclosure - Note 15 - Subsequent Events - 10-Q (Details Textual)", "shortName": "Note 15 - Subsequent Events - 10-Q (Details Textual)", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "details", "menuCat": "Details", "order": "136", "firstAnchor": { "contextRef": "d_2025-01-01_2025-12-31", "name": "us-gaap:ProceedsFromIssuanceOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2026-05-06_2026-05-06_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "pmi20260519_s1.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountingPoliciesAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": [ "r1315" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r1134", "r1196", "r1199" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsReceivableMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r991", "r1301" ] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccountsReceivableNet", "terseLabel": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r914", "r990", "r1158", "r1542", "r1543" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccountsReceivableNetCurrent", "terseLabel": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1312" ] }, "pmi_AccruedClinicalAndManufacturingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "AccruedClinicalAndManufacturingExpenses", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Accrued clinical and manufacturing expenses", "documentation": "Accrued clinical and manufacturing expenses." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Accrued professional and consulting services", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r1200" ] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Accrued compensation", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r1012", "r1200" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less: accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion, and amortization of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r96", "r295", "r299", "r812", "r813", "r828", "r1334" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r11", "r12", "r31", "r123", "r390", "r788", "r789", "r800", "r823", "r853", "r857", "r1486" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r7", "r12", "r623", "r626", "r629", "r717", "r848", "r849", "r1224", "r1225", "r1226", "r1292", "r1293", "r1294", "r1295", "r1366", "r1368" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r121", "r390", "r788", "r789", "r800", "r1134", "r1586" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r814", "r875", "r1292", "r1293", "r1294", "r1295", "r1487", "r1588" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentForAmortization", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AdjustmentForAmortization", "terseLabel": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r5" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r471" ] }, "pmi_AdjustmentsToAdditionalPaidInCapitalWriteoffOfRelatedPartyReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "AdjustmentsToAdditionalPaidInCapitalWriteoffOfRelatedPartyReceivable", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Write off of related party note receivable", "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) from write-off of related party receivable." } } }, "auth_ref": [] }, "pmi_AggregatedConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "AggregatedConvertibleNoteMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Aggregated Convertible Note [Member]", "documentation": "Aggregated Convertible Note" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_AllocatedShareBasedCompensationExpense", "terseLabel": "Stock-based compensation", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r503", "r512", "r522" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AmendmentFlag", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Amortization of discount on debt issued", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r5", "r38", "r344", "r1514" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Financing charges from issuance of senior secured note", "terseLabel": "Amortization of Debt Issuance Costs", "negatedLabel": "Financing charges", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r38", "r344", "r1275", "r1514" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AmortizationOfFinancingCostsAndDiscounts", "terseLabel": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r344", "r1056", "r1057", "r1275", "r1514" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_AmortizationOfIntangibleAssets", "terseLabel": "Amortization of Intangible Assets", "documentation": "Amount of amortization expense for finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r5", "r146", "r268", "r275", "r1007", "r1019", "r1021", "r1023", "r1025", "r1334" ] }, "pmi_AmortizationPeriodResearchAndDevelopmentCosts": { "xbrltype": "durationItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "AmortizationPeriodResearchAndDevelopmentCosts", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_AmortizationPeriodResearchAndDevelopmentCosts", "terseLabel": "Amortization Period, Research and Development Costs (Year)", "documentation": "The period for which the research and development costs will be amortized." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-10q-details", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Shares excluded from computation (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r203" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-10q-details", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r203" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-10q-details", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r203" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r589" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetAcquisitionAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r264", "r269", "r270", "r271", "r272", "r273", "r860", "r1477" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetAcquisitionDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r264", "r269", "r270", "r271", "r272", "r273", "r860", "r1477" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Assets", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r80", "r81", "r99", "r161", "r163", "r164", "r209", "r221", "r234", "r235", "r243", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r393", "r590", "r592", "r682", "r788", "r789", "r792", "r807", "r808", "r818", "r919", "r1037", "r1038", "r1058", "r1134", "r1152", "r1153", "r1166", "r1352", "r1353", "r1520" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r80", "r81", "r129", "r161", "r163", "r164", "r243", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r393", "r590", "r592", "r682", "r1134", "r1192", "r1352", "r1353", "r1520" ] }, "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AuctionMarketPreferredSecuritiesStockSeriesTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-tables", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-reserved-common-stock-10q-details", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-reserved-common-stock-details", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-tables" ], "lang": { "en-us": { "role": { "label": "Auction Market Preferred Securities, Stock Series [Table]", "documentation": "Disclosure of information about auction market preferred security. Includes, but is not limited to, liquidation preference, liquidation value, par value, rate setting interval, redemption requirement, dividend distribution, shares authorized and outstanding, aggregate value of auction market preferred security, and variable interest rate earned." } } }, "auth_ref": [ "r1362", "r1363" ] }, "us-gaap_AustralianTaxationOfficeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AustralianTaxationOfficeMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details" ], "lang": { "en-us": { "role": { "label": "Australian Taxation Office [Member]", "documentation": "Designated tax department of the government of Australia." } } }, "auth_ref": [ "r1466", "r1470" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AwardTypeAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-valuation-assumptions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r474", "r475", "r476", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r499", "r500", "r501", "r502" ] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BuildingMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-details" ], "lang": { "en-us": { "role": { "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r1046", "r1340", "r1341" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q" ], "lang": { "en-us": { "role": { "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r1187", "r1280" ] }, "country_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2026", "localname": "CA", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual" ], "lang": { "en-us": { "role": { "label": "CANADA" } } }, "auth_ref": [] }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CaliforniaFranchiseTaxBoardMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details" ], "lang": { "en-us": { "role": { "label": "California Franchise Tax Board [Member]", "documentation": "Designated tax department of the government of the state of California." } } }, "auth_ref": [ "r1466", "r1470" ] }, "pmi_CapitalRaise": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CapitalRaise", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_CapitalRaise", "terseLabel": "Capital Raise" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents", "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r94", "r154", "r158", "r1009", "r1522" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r155" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r1276" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the period", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the period", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r41", "r154", "r158" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash, cash equivalents and restricted cash at end of the period" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r0", "r41" ] }, "pmi_ChangeInFairValueOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ChangeInFairValueOfDebt", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ChangeInFairValueOfDebt", "terseLabel": "Change in Fair Value of Debt", "documentation": "The change in fair value of debt over a period of time." } } }, "auth_ref": [] }, "pmi_ChangeInFairValueOfDebtAndWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ChangeInFairValueOfDebtAndWarrantLiability", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Change in fair values of senior secured note and warrant liabilities", "negatedLabel": "Change in fair values of senior secured note and warrant liabilities", "documentation": "The amount of change in fair value of debt and warrant liability." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CityAreaCode", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfStockDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-reserved-common-stock-10q-details", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-reserved-common-stock-details" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r70", "r86", "r87", "r114", "r115", "r116", "r117", "r118", "r119", "r161", "r164", "r195", "r196", "r199", "r201", "r211", "r212", "r243", "r313", "r315", "r316", "r317", "r320", "r321", "r354", "r355", "r357", "r358", "r360", "r363", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r376", "r379", "r382", "r383", "r384", "r385", "r386", "r388", "r389", "r392", "r393", "r394", "r682", "r788", "r789", "r797", "r798", "r799", "r814", "r866", "r867", "r868", "r869", "r875", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r906", "r927", "r949", "r978", "r979", "r980", "r981", "r982", "r1181", "r1283", "r1285", "r1296", "r1367", "r1372" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r1362" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [ "r1362" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r161", "r167", "r383" ] }, "pmi_ClassOfWarrantOrRightExercisedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ClassOfWarrantOrRightExercisedInPeriod", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ClassOfWarrantOrRightExercisedInPeriod", "terseLabel": "Class of Warrant or Right, Exercised in Period (in shares)", "documentation": "Number of warrants or rights exercised during the period." } } }, "auth_ref": [] }, "pmi_ClassOfWarrantOrRightIssuedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ClassOfWarrantOrRightIssuedDuringPeriod", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ClassOfWarrantOrRightIssuedDuringPeriod", "terseLabel": "Class of Warrant or Right, Issued During Period (in shares)", "documentation": "The number of warrants or rights issued during period." } } }, "auth_ref": [] }, "pmi_ClassOfWarrantOrRightIssuedDuringPeriodFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ClassOfWarrantOrRightIssuedDuringPeriodFairValue", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ClassOfWarrantOrRightIssuedDuringPeriodFairValue", "terseLabel": "Class of Warrant or Right, Issued During Period, Fair Value", "documentation": "The fair value of warrants or rights issued during the period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r1362" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 7)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r113", "r788", "r789", "r796", "r820", "r905" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r305", "r306", "r992", "r1343", "r1348", "r1349" ] }, "pmi_CommonSharesIssuableUponConversionOfNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CommonSharesIssuableUponConversionOfNotesMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-10q-details", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Common Shares Issuable Upon Conversion of Notes [Member]", "documentation": "Common Shares Issuable Upon Conversion of Notes" } } }, "auth_ref": [] }, "pmi_CommonSharesIssuableUponExerciseOfCommonStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CommonSharesIssuableUponExerciseOfCommonStockOptionsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-10q-details", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Common Shares Issuable Upon Exercise of Common Stock Options [Member]", "documentation": "Common Shares Issuable Upon Exercise of Common Stock Options" } } }, "auth_ref": [] }, "pmi_CommonSharesIssuableUponExerciseOfIssuedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CommonSharesIssuableUponExerciseOfIssuedWarrantsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-10q-details", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Common Shares Issuable Upon Exercise of Issued Warrants [Member]", "documentation": "Represents the Common shares issuable upon exercise of issued warrants." } } }, "auth_ref": [] }, "pmi_CommonStockAvailableForFutureGrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CommonStockAvailableForFutureGrantsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-reserved-common-stock-10q-details", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-reserved-common-stock-details" ], "lang": { "en-us": { "role": { "label": "Common Stock Available for Future Grants [Member]", "documentation": "Common Stock Available for Future Grants" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-reserved-common-stock-10q-details", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-reserved-common-stock-details" ], "lang": { "en-us": { "role": { "label": "Reserved common stock (in shares)", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r1362" ] }, "pmi_CommonStockFromOptionsIssuedAndOutstandingMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CommonStockFromOptionsIssuedAndOutstandingMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-reserved-common-stock-10q-details", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-reserved-common-stock-details" ], "lang": { "en-us": { "role": { "label": "Common Stock from Options Issued and Outstanding [Member]", "documentation": "Common Stock from Options Issued and Outstanding" } } }, "auth_ref": [] }, "pmi_CommonStockIssuedFromConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CommonStockIssuedFromConvertibleNotesMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-reserved-common-stock-details" ], "lang": { "en-us": { "role": { "label": "Common Stock Issued from Convertible Notes [Member]", "documentation": "Common Stock Issued from Convertible Notes" } } }, "auth_ref": [] }, "pmi_CommonStockIssuedFromIssuedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CommonStockIssuedFromIssuedWarrantsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-reserved-common-stock-10q-details", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-reserved-common-stock-details" ], "lang": { "en-us": { "role": { "label": "Common Stock Issued from Issued Warrants [Member]", "documentation": "Represents the shares issued from the issued warrants." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r119", "r389", "r788", "r789", "r799", "r1155", "r1156", "r1157", "r1159", "r1160", "r1161", "r1162", "r1292", "r1293", "r1295", "r1487", "r1584", "r1588" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r1207", "r1365", "r1529", "r1530", "r1536" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r119", "r389", "r788", "r789", "r799", "r906" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesIssued", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r119", "r389", "r788", "r789", "r799" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Common stock, outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r119", "r389", "r788", "r789", "r799", "r906", "r925", "r1361", "r1588", "r1589" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.0001 par value; 150,000,000 shares authorized; 73,701,176 and 9,286,235 shares issued as of December 31, 2025 and 2024, respectively, of which 73,701,176 and 7,943,585 are outstanding as of December 31, 2025 and 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r119", "r355", "r362", "r389", "r788", "r789", "r799", "r821", "r1134" ] }, "pmi_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CommonStockWarrantsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Common Stock Warrants [Member]", "documentation": "Represents common stock warrants." } } }, "auth_ref": [] }, "pmi_Company401kPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "Company401kPlanMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Company 401k Plan [Member]", "documentation": "Company 401k Plan" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ComponentsOfDeferredTaxAssetsAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets:" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities:" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r13", "r133", "r135", "r140", "r805", "r833", "r834" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Loss:" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r215", "r240", "r861", "r862", "r991", "r1300", "r1301", "r1302", "r1303", "r1304" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r215", "r240", "r861", "r862", "r991", "r1300", "r1301", "r1302", "r1303", "r1304" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r215", "r240", "r861", "r862", "r991", "r1300", "r1301", "r1302", "r1303", "r1304" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument." } } }, "auth_ref": [ "r676", "r679" ] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Disclosure [Text Block]", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": [ "r213", "r217", "r675", "r677", "r678", "r680", "r681", "r1030", "r1299" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r215", "r240", "r1300", "r1301", "r1302", "r1303", "r1304" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConcentrationRiskTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-tables", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-tables" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r215", "r216", "r991", "r1029", "r1300", "r1301", "r1302", "r1303", "r1304" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r215", "r240", "r861", "r862", "r991", "r1300", "r1301", "r1302", "r1303", "r1304" ] }, "pmi_ConsolidatedFangFamilyFundLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ConsolidatedFangFamilyFundLoansMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Consolidated Fang Family Fund Loans [Member]", "documentation": "Consolidated Fang Family Fund Loans" } } }, "auth_ref": [] }, "pmi_ContractTerminationInterestPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ContractTerminationInterestPaid", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ContractTerminationInterestPaid", "terseLabel": "Contract Termination, Interest Paid", "documentation": "The interest paid on the contract termination payable." } } }, "auth_ref": [] }, "us-gaap_ContractTerminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ContractTerminationMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "Contract Termination [Member]", "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [ "r1020", "r1049", "r1050", "r1051", "r1052" ] }, "pmi_ContractTerminationMonthlyInterest": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ContractTerminationMonthlyInterest", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ContractTerminationMonthlyInterest", "terseLabel": "Contract Termination, Monthly Interest", "documentation": "The monthly interest payable on late payments of the terminated contract payable." } } }, "auth_ref": [] }, "pmi_ContractTerminationPayableTerm": { "xbrltype": "durationItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ContractTerminationPayableTerm", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ContractTerminationPayableTerm", "terseLabel": "Contract Termination Payable, Term (Year)", "documentation": "The length of time that the contract termination payable will be paid off." } } }, "auth_ref": [] }, "pmi_ContractTerminationPenalty": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ContractTerminationPenalty", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ContractTerminationPenalty", "terseLabel": "Contract Termination Penalty", "documentation": "The amount of termination penalty for the contract termination." } } }, "auth_ref": [] }, "pmi_ContractTerminationPenaltyPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ContractTerminationPenaltyPaid", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ContractTerminationPenaltyPaid", "terseLabel": "Contract Termination, Penalty Paid", "documentation": "The amount of penalty paid on contract termination." } } }, "auth_ref": [] }, "pmi_ContractTerminationRefundForReturnInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ContractTerminationRefundForReturnInventory", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ContractTerminationRefundForReturnInventory", "terseLabel": "Contract Termination, Refund for Return Inventory", "documentation": "Amount of refund for returned inventory for contract termination." } } }, "auth_ref": [] }, "pmi_ContractTerminationReturnedInventoryRefund": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ContractTerminationReturnedInventoryRefund", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ContractTerminationReturnedInventoryRefund", "terseLabel": "Contract Termination, Returned Inventory Refund", "documentation": "The refunded returned inventory." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ContractWithCustomerLiability", "terseLabel": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r408", "r409", "r411", "r423" ] }, "pmi_ConversionOf20232024ConvertibleNotesAndAggregatedNotesIntoCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ConversionOf20232024ConvertibleNotesAndAggregatedNotesIntoCommonStockMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of 2023, 2024 Convertible Notes and Aggregated Notes into Common Stock [Member]", "documentation": "Represents information pertaining to the conversion of 2023, 2024 convertible notes and aggregated notes into common stock." } } }, "auth_ref": [] }, "pmi_ConversionOfConvertibleNoteToCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ConversionOfConvertibleNoteToCommonStockMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Conversion of Convertible Note to Common Stock [Member]", "documentation": "Related to debt conversion." } } }, "auth_ref": [] }, "pmi_ConversionOfDebtIntoCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ConversionOfDebtIntoCommonStockMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Conversion of Debt into Common Stock [Member]", "documentation": "Represents the conversion of debt into common stock." } } }, "auth_ref": [] }, "pmi_ConversionOfSeniorSecuredNotesIntoCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ConversionOfSeniorSecuredNotesIntoCommonStockMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of Senior Secured Notes into Common Stock [Member]", "documentation": "Represents the conversion of senior secured notes into common stock." } } }, "auth_ref": [] }, "pmi_ConversionOfSeriesA1PreferredStockToCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ConversionOfSeriesA1PreferredStockToCommonStockMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of Series A-1 Preferred Stock to Common Stock [Member]", "documentation": "Related to stock conversion." } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockAmountConverted1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConversionOfStockAmountConverted1", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Preferred stock conversion to common stock", "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r1279" ] }, "us-gaap_ConversionOfStockAmountIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConversionOfStockAmountIssued1", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "us-gaap_ConversionOfStockAmountIssued1", "terseLabel": "Preferred Stock Conversion to Common Stock", "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r1279" ] }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConversionOfStockByUniqueDescriptionAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Stock Conversion Description [Axis]", "documentation": "Information by description of stock conversions." } } }, "auth_ref": [ "r1279" ] }, "us-gaap_ConversionOfStockNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConversionOfStockNameDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of Stock, Name [Domain]", "documentation": "The unique name of a noncash or part noncash stock conversion." } } }, "auth_ref": [ "r1279" ] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConversionOfStockSharesIssued1", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ConversionOfStockSharesIssued1", "terseLabel": "Conversion of Stock, Shares Issued (in shares)", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r1279" ] }, "pmi_ConversionOfTemporaryPreferredStockIntoCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ConversionOfTemporaryPreferredStockIntoCommonMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of Temporary Preferred Stock into Common [Member]", "documentation": "Conversion of Temporary Preferred Stock into Common" } } }, "auth_ref": [] }, "pmi_ConversionOfTheAnotherDimensionNoteToCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ConversionOfTheAnotherDimensionNoteToCommonStockMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of the Another Dimension Note to Common Stock [Member]", "documentation": "Related to debt conversion." } } }, "auth_ref": [] }, "pmi_ConversionOfTheNexusNoteToCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ConversionOfTheNexusNoteToCommonStockMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Conversion of the Nexus Note to Common Stock [Member]", "documentation": "Related to debt conversion." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ConvertibleDebt", "terseLabel": "Subtotal", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r1197", "r1202", "r1529", "r1530", "r1533", "r1540" ] }, "us-gaap_ConvertibleDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConvertibleDebtCurrent", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ConvertibleDebtCurrent", "negatedTerseLabel": "Less: Current portion", "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r1200" ] }, "pmi_ConvertibleDebtInstrumentConversionPriceEqualToLowestPricePerShare": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ConvertibleDebtInstrumentConversionPriceEqualToLowestPricePerShare", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ConvertibleDebtInstrumentConversionPriceEqualToLowestPricePerShare", "terseLabel": "Convertible Debt Instrument, Conversion Price Equal to Lowest Price per Share", "documentation": "The conversion price, equal to a percentage of the lowest price per share." } } }, "auth_ref": [] }, "pmi_ConvertibleDebtInstrumentConversionPriceEqualToLowestPricePerSharePrestockSplit": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ConvertibleDebtInstrumentConversionPriceEqualToLowestPricePerSharePrestockSplit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ConvertibleDebtInstrumentConversionPriceEqualToLowestPricePerSharePrestockSplit", "terseLabel": "Convertible Debt Instrument, Conversion Price Equal to Lowest Price per Share, Pre-stock Split", "documentation": "The pre-stock split conversion price, equal to a percentage of the lowest price per share." } } }, "auth_ref": [] }, "pmi_ConvertibleDebtInstrumentPrincipalRaised": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ConvertibleDebtInstrumentPrincipalRaised", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ConvertibleDebtInstrumentPrincipalRaised", "terseLabel": "Convertible Debt Instrument, Principal Raised", "documentation": "Convertible Debt Instrument, Principal Raised" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConvertibleDebtNoncurrent", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ConvertibleDebtNoncurrent", "terseLabel": "Debt, net of current portion", "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock." } } }, "auth_ref": [ "r1197", "r1202" ] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConvertibleDebtTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-tables" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Table Text Block]", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "pmi_ConvertibleNoteDonatedValueReceivedInShares": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ConvertibleNoteDonatedValueReceivedInShares", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ConvertibleNoteDonatedValueReceivedInShares", "terseLabel": "Convertible Note, Donated Value Received in Shares", "documentation": "Convertible Note, Donated Value Received in Shares" } } }, "auth_ref": [] }, "pmi_ConvertibleNotePayable2026Member": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ConvertibleNotePayable2026Member", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "Convertible Note Payable 2026 [Member]", "documentation": "Represents the 2026 convertible note payable." } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Convertible notes payable, net", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r1200" ] }, "us-gaap_CostOfGoodsAndServicesSoldAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CostOfGoodsAndServicesSoldAmortization", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_CostOfGoodsAndServicesSoldAmortization", "terseLabel": "Cost, Amortization", "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service." } } }, "auth_ref": [ "r1227" ] }, "us-gaap_CostOfGoodsAndServicesSoldDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CostOfGoodsAndServicesSoldDepreciation", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_CostOfGoodsAndServicesSoldDepreciation", "terseLabel": "Cost, Depreciation", "documentation": "Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service." } } }, "auth_ref": [ "r1227", "r1339" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Cost of revenues", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r34", "r161", "r163", "r164", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r393", "r682", "r1037", "r1189", "r1190", "r1317", "r1352" ] }, "us-gaap_CostOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CostOfRevenueAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Cost of revenues:" } } }, "auth_ref": [] }, "pmi_CostOfRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CostOfRevenueMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-10q-details" ], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Member]", "documentation": "Represents cost of revenue." } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CostOfSalesMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Cost of Sales [Member] (Deprecated 2026)", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Service [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r1185" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "CounterpartyNameAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r161", "r170", "r171", "r326", "r373", "r724", "r730", "r745", "r817", "r1015", "r1017", "r1018", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1480", "r1481", "r1482", "r1483", "r1523", "r1524" ] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CurrentFederalTaxExpenseBenefit", "terseLabel": "Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1184", "r1281", "r1287", "r1474" ] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CurrentForeignTaxExpenseBenefit", "terseLabel": "Foreign", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r1184", "r1281", "r1287" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CurrentIncomeTaxExpenseBenefit", "totalLabel": "Total Current", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r560", "r1281", "r1287" ] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_CurrentStateAndLocalTaxExpenseBenefit", "terseLabel": "State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1184", "r1281", "r1287", "r1474" ] }, "pmi_CustomerAMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CustomerAMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details" ], "lang": { "en-us": { "role": { "label": "Customer A [Member]", "documentation": "Customer A" } } }, "auth_ref": [] }, "pmi_CustomerBMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CustomerBMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details" ], "lang": { "en-us": { "role": { "label": "Customer B [Member]", "documentation": "Customer B" } } }, "auth_ref": [] }, "pmi_CustomerCMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CustomerCMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details" ], "lang": { "en-us": { "role": { "label": "Customer C [Member]", "documentation": "Customer C" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r240", "r1301" ] }, "pmi_CustomerEMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CustomerEMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer E [Member]", "documentation": "Customer E" } } }, "auth_ref": [] }, "pmi_CustomerFMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CustomerFMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer F [Member]", "documentation": "Customer F" } } }, "auth_ref": [] }, "pmi_CustomerHMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CustomerHMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual" ], "lang": { "en-us": { "role": { "label": "Customer H [Member]", "documentation": "Represents customer H." } } }, "auth_ref": [] }, "pmi_CustomerIMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CustomerIMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details" ], "lang": { "en-us": { "role": { "label": "Customer I [Member]", "documentation": "Related to customer I." } } }, "auth_ref": [] }, "pmi_CustomerJMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "CustomerJMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details" ], "lang": { "en-us": { "role": { "label": "Customer J [Member]", "documentation": "Customer J." } } }, "auth_ref": [] }, "country_DE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2026", "localname": "DE", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual" ], "lang": { "en-us": { "role": { "label": "GERMANY" } } }, "auth_ref": [] }, "pmi_DanielTeoSeveranceLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DanielTeoSeveranceLoanMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Daniel Teo Severance Loan [Member]", "documentation": "Daniel Teo Severance Loan" } } }, "auth_ref": [] }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtConversionByUniqueDescriptionAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Debt Conversion Description [Axis]", "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction." } } }, "auth_ref": [ "r1279" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionConvertedInstrumentSharesIssued1", "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued (in shares)", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r1279" ] }, "pmi_DebtConversionConvertedInstrumentSharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DebtConversionConvertedInstrumentSharesIssuedPricePerShare", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_DebtConversionConvertedInstrumentSharesIssuedPricePerShare", "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued, Price Per Share (in dollars per share)", "documentation": "The price per share of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [] }, "us-gaap_DebtConversionNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtConversionNameDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Debt Conversion, Name [Domain]", "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r1279" ] }, "us-gaap_DebtConversionOriginalDebtAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtConversionOriginalDebtAmount1", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtConversionOriginalDebtAmount1", "terseLabel": "Debt Conversion, Original Debt, Amount", "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r1279" ] }, "pmi_DebtConversionOriginalDebtInterestAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DebtConversionOriginalDebtInterestAmount", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_DebtConversionOriginalDebtInterestAmount", "terseLabel": "Debt Conversion, Original Debt Interest, Amount", "documentation": "The amount of the original debt interest being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r46", "r92", "r93", "r101", "r102", "r105", "r107", "r108", "r110", "r111", "r161", "r162", "r300", "r301", "r302", "r303", "r304", "r311", "r312", "r322", "r328", "r329", "r330", "r331", "r332", "r333", "r338", "r345", "r346", "r348", "r619", "r691", "r788", "r789", "r795" ] }, "pmi_DebtInstrumentAmendedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DebtInstrumentAmendedAmount", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_DebtInstrumentAmendedAmount", "terseLabel": "Debt Instrument, Amended Amount", "documentation": "The amount of the debt instrument that was amended." } } }, "auth_ref": [] }, "pmi_DebtInstrumentAmountThatCanBeSettledInShares": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DebtInstrumentAmountThatCanBeSettledInShares", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_DebtInstrumentAmountThatCanBeSettledInShares", "terseLabel": "Debt Instrument, Amount That Can Be Settled in Shares", "documentation": "The amount of debt that can be settled by the issuance of shares." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details-parentheticals", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r92", "r93", "r101", "r105", "r106", "r107", "r108", "r109", "r111", "r323", "r324", "r325", "r326", "r327", "r329", "r334", "r335", "r336", "r337", "r339", "r340", "r341", "r342", "r343", "r344", "r383", "r788", "r789", "r795", "r1053", "r1054", "r1055", "r1056", "r1057", "r1124", "r1281", "r1282", "r1284", "r1291", "r1344", "r1345", "r1346", "r1513", "r1515", "r1538" ] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details-parentheticals", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details" ], "lang": { "en-us": { "role": { "label": "Unpaid principal", "terseLabel": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r349", "r1529", "r1530", "r1533" ] }, "pmi_DebtInstrumentConvertibleAddOnValueEachConversion": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DebtInstrumentConvertibleAddOnValueEachConversion", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_DebtInstrumentConvertibleAddOnValueEachConversion", "terseLabel": "Debt Instrument, Convertible, Add on Value, Each Conversion", "documentation": "Represents the addon value for each conversion of a convertible debt instrument." } } }, "auth_ref": [] }, "pmi_DebtInstrumentConvertibleOneTimeInterestCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DebtInstrumentConvertibleOneTimeInterestCharge", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_DebtInstrumentConvertibleOneTimeInterestCharge", "terseLabel": "Debt Instrument, Convertible, One Time Interest Charge", "documentation": "Represents the amount of a one time interest charge related to a convertible debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "terseLabel": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentConvertibleThresholdTradingDays", "terseLabel": "Debt Instrument, Convertible, Threshold Trading Days", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "pmi_DebtInstrumentCovenantLiquidityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DebtInstrumentCovenantLiquidityAmount", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_DebtInstrumentCovenantLiquidityAmount", "terseLabel": "Debt Instrument, Covenant, Liquidity Amount", "documentation": "Requirement to maintain a minimum liquidity amount under the debt agreement." } } }, "auth_ref": [] }, "pmi_DebtInstrumentDefaultInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DebtInstrumentDefaultInterestRate", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_DebtInstrumentDefaultInterestRate", "terseLabel": "Debt Instrument, Default, Interest Rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement, in the event of a default." } } }, "auth_ref": [] }, "pmi_DebtInstrumentDivisor": { "xbrltype": "decimalItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DebtInstrumentDivisor", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_DebtInstrumentDivisor", "terseLabel": "Debt Instrument, Divisor", "documentation": "The divisor of the convertible debt instrument." } } }, "auth_ref": [] }, "pmi_DebtInstrumentExternalFundingReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DebtInstrumentExternalFundingReceived", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_DebtInstrumentExternalFundingReceived", "terseLabel": "Debt Instrument, External Funding Received", "documentation": "The amount of external funding received." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r323", "r691", "r692", "r1054", "r1055", "r1124" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r93", "r105", "r324", "r788", "r789", "r795" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details-parentheticals", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r92", "r93", "r101", "r105", "r106", "r107", "r108", "r109", "r111", "r323", "r324", "r325", "r326", "r327", "r329", "r334", "r335", "r336", "r337", "r339", "r340", "r341", "r342", "r343", "r344", "r383", "r788", "r789", "r795", "r1053", "r1054", "r1055", "r1056", "r1057", "r1124", "r1281", "r1282", "r1284", "r1291", "r1344", "r1345", "r1346", "r1513", "r1515", "r1538" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentPeriodicPayment", "terseLabel": "Debt Instrument, Periodic Payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r30", "r1197", "r1201" ] }, "pmi_DebtInstrumentQualifiedEquityFinancingPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DebtInstrumentQualifiedEquityFinancingPeriodicPayment", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_DebtInstrumentQualifiedEquityFinancingPeriodicPayment", "terseLabel": "Debt Instrument, Qualified Equity Financing, Periodic Payment", "documentation": "Amount of the required periodic payments including both interest and principal payments if a qualified equity financing is completed." } } }, "auth_ref": [] }, "pmi_DebtInstrumentRepurchasePricePercent": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DebtInstrumentRepurchasePricePercent", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_DebtInstrumentRepurchasePricePercent", "terseLabel": "Debt Instrument, Repurchase Price, Percent", "documentation": "The repurchase price of the debt expressed as a percentage of the outstanding debt." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details", "http://picardmedical.com/20260331/role/statement-note-8-debt-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r29", "r57", "r58", "r59", "r93", "r105", "r106", "r107", "r108", "r109", "r111", "r323", "r324", "r325", "r326", "r327", "r329", "r334", "r335", "r336", "r337", "r339", "r340", "r341", "r342", "r343", "r344", "r347", "r383", "r619", "r788", "r789", "r795", "r811", "r1053", "r1054", "r1055", "r1056", "r1057", "r1124", "r1281", "r1282", "r1284", "r1291", "r1513", "r1515" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentTerm", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentTerm", "terseLabel": "Debt Instrument, Term (Year)", "documentation": "Period between issuance and maturity of debt instrument, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentUnamortizedDiscount", "terseLabel": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r1355", "r1512", "r1513", "r1515" ] }, "pmi_DebtInstrumentUnamortizedDiscountPercent": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DebtInstrumentUnamortizedDiscountPercent", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_DebtInstrumentUnamortizedDiscountPercent", "terseLabel": "Debt Instrument, Unamortized Discount, Percent", "documentation": "Amount, after accumulated amortization, of debt discount expressed as a percentage of face value." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet", "negatedTerseLabel": "Less: unamortized debt discount", "documentation": "Amount, after accumulated amortization, of debt discount (premium)." } } }, "auth_ref": [ "r1355", "r1512", "r1513", "r1515" ] }, "pmi_DebtInstrumentUnpaidPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DebtInstrumentUnpaidPrincipal", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details-parentheticals" ], "lang": { "en-us": { "role": { "verboseLabel": "Unpaid principal", "label": "pmi_DebtInstrumentUnpaidPrincipal", "documentation": "The unpaid principal portion of long-term debt." } } }, "auth_ref": [] }, "pmi_DebtPrincipalAmountAccelerated": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DebtPrincipalAmountAccelerated", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_DebtPrincipalAmountAccelerated", "terseLabel": "Debt, Principal Amount Accelerated", "documentation": "The principal amount accelerated of debt." } } }, "auth_ref": [] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "terseLabel": "Federal", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1281", "r1287", "r1473", "r1474" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredFinanceCostsNet", "terseLabel": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1355", "r1512", "r1513", "r1515" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredIncomeTaxExpenseBenefit", "totalLabel": "Total Deferred", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r5", "r67", "r1281", "r1287" ] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Total Deferred Tax Liability", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r551" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "terseLabel": "State", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1281", "r1287", "r1473", "r1474" ] }, "pmi_DeferredTaxAssetsCapitalizedResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "pmi_DeferredTaxAssetsCapitalizedResearchAndDevelopment", "terseLabel": "Capitalized research", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development." } } }, "auth_ref": [] }, "pmi_DeferredTaxAssetsDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DeferredTaxAssetsDebtIssuanceCosts", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "pmi_DeferredTaxAssetsDebtIssuanceCosts", "terseLabel": "Debt Issuance Costs", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from debt issuance costs." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Gross deferred income tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r552" ] }, "us-gaap_DeferredTaxAssetsInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxAssetsInventory", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsInventory", "terseLabel": "Inventory allowance", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory." } } }, "auth_ref": [ "r1471" ] }, "pmi_DeferredTaxAssetsLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DeferredTaxAssetsLeaseLiability", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "pmi_DeferredTaxAssetsLeaseLiability", "terseLabel": "Right-of-use Lease liability", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net Deferred Income Tax Assets, net of valuation allowance", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r1467" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Net Deferred Income Tax Assets, net of valuation allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1467" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards", "terseLabel": "Net operating loss carry-forwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r1471" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsOther", "terseLabel": "Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r1471" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch", "terseLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r1471" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "terseLabel": "Stock based Compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r1471" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "terseLabel": "Accruals and reserves", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals." } } }, "auth_ref": [ "r1471" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Less: Valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r553" ] }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxLiabilitiesLeasingArrangements", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements", "negatedLabel": "Right-of-use asset", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements." } } }, "auth_ref": [ "r1471" ] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedLabel": "Depreciation and amortization", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r1471" ] }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DefinedBenefitPlanContributionsByEmployer", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DefinedBenefitPlanContributionsByEmployer", "terseLabel": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets." } } }, "auth_ref": [ "r435", "r438", "r451", "r452", "r456", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072" ] }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "documentation": "Disclosure of information about defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans." } } }, "auth_ref": [ "r6", "r23", "r24", "r25", "r26" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r145", "r293", "r1019", "r1021", "r1023", "r1025" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_DepreciationDepletionAndAmortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r5", "r147", "r209", "r224", "r235", "r1019", "r1037", "r1038", "r1329", "r1334", "r1339", "r1341" ] }, "pmi_DerecognitionOfDerivativeLiabilityFromConversionOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DerecognitionOfDerivativeLiabilityFromConversionOfDebt", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Derecognition of derivative liability upon conversion of convertible notes", "documentation": "The amount of derecognition of derivative liability from conversion of debt." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r144", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r743", "r895", "r897", "r911", "r912", "r913", "r915", "r916", "r917", "r918", "r920", "r921", "r922", "r923", "r937", "r938", "r939", "r940", "r943", "r944", "r945", "r946", "r967", "r968", "r971", "r973", "r1014", "r1015", "r1018", "r1113", "r1114", "r1135", "r1155", "r1157", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1480", "r1481", "r1482", "r1483", "r1493", "r1494", "r1495", "r1496", "r1497", "r1498", "r1501", "r1502" ] }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments, Liabilities [Member]", "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect." } } }, "auth_ref": [ "r667" ] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_DerivativeGainLossOnDerivativeNet", "negatedLabel": "Derivative loss", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r1122", "r1479" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r144", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r743", "r895", "r897", "r911", "r912", "r913", "r915", "r916", "r917", "r918", "r920", "r921", "r922", "r923", "r937", "r938", "r939", "r940", "r943", "r944", "r945", "r946", "r967", "r968", "r971", "r973", "r1014", "r1015", "r1018", "r1113", "r1114", "r1135", "r1155", "r1157", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1480", "r1481", "r1482", "r1483", "r1493", "r1494", "r1495", "r1496", "r1497", "r1498", "r1501", "r1502" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Warrant Liabilities", "terseLabel": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r130", "r131", "r618", "r654", "r655", "r666", "r672", "r673", "r674", "r888", "r889", "r890", "r891", "r893", "r894", "r895", "r896", "r897", "r920", "r922", "r923", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r1014", "r1016", "r1017", "r1018", "r1490", "r1491", "r1492", "r1585" ] }, "us-gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DerivativeLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Derivative liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r131" ] }, "us-gaap_DerivativeLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DerivativeLiabilityMeasurementInput", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Significant Unobservable Inputs", "documentation": "Value of input used to measure derivative liability." } } }, "auth_ref": [ "r656", "r657", "r658" ] }, "pmi_DerivativeLiabilityRecognizedOnIssuanceOfConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "DerivativeLiabilityRecognizedOnIssuanceOfConvertibleNotes", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Derivative liability recognized on issuance of convertible notes", "documentation": "Derivative Liability Recognized on Issuance of Convertible Notes." } } }, "auth_ref": [] }, "us-gaap_DerivativesEmbeddedDerivatives": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DerivativesEmbeddedDerivatives", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Derivatives, Embedded Derivatives [Policy Text Block]", "documentation": "Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts." } } }, "auth_ref": [ "r1478", "r1484", "r1485" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r1321", "r1322", "r1323", "r1324", "r1326", "r1328", "r1332", "r1333", "r1475" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r421", "r422", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-tables", "http://picardmedical.com/20260331/role/statement-note-5-revenue-tables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1373" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r469", "r473", "r504", "r505", "r507", "r1074" ] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-10q", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-10q", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_DividendsPayableCurrentAndNoncurrent", "terseLabel": "Dividends Payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": [ "r1163", "r1203", "r1529", "r1530", "r1532", "r1539" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentInformationLineItems", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentType", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DomesticCountryMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction, Domestic Federal [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r534" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareBasic", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Net loss per share\u2014basic and diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r78", "r141", "r177", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r193", "r195", "r199", "r200", "r201", "r208", "r290", "r353", "r429", "r510", "r578", "r588", "r650", "r651", "r806", "r835", "r1028" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r204" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-10q" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r192", "r203", "r205", "r206", "r207", "r398" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r1511" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "totalLabel": "Income Tax Provision/(Benefit) and Effective Income Tax Rate, percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r534", "r1078" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "U.S. Federal statutory income tax (benefit), percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r161", "r166", "r534", "r566", "r1078" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r540", "r1078", "r1281", "r1288", "r1462" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Effects of change in state tax rate, net of federal benefits, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates." } } }, "auth_ref": [ "r538", "r1078", "r1281", "r1288", "r1462" ] }, "pmi_EffectiveIncomeTaxRateReconciliationFMVAdjustmentDerivativeAndWarrantLiabilityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "EffectiveIncomeTaxRateReconciliationFMVAdjustmentDerivativeAndWarrantLiabilityAmount", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Changes in fair values - derivative & warrant liabilities, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to FMV adjustment derivative and warrant liability." } } }, "auth_ref": [] }, "pmi_EffectiveIncomeTaxRateReconciliationFMVAdjustmentDerivativeAndWarrantLiabilityPercent": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "EffectiveIncomeTaxRateReconciliationFMVAdjustmentDerivativeAndWarrantLiabilityPercent", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Changes in fair values - derivative & warrant liabilities", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to FMV adjustment derivative and warrant liability." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Foreign Rate Differential, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile." } } }, "auth_ref": [ "r537", "r542", "r1078", "r1281", "r1288", "r1462" ] }, "pmi_EffectiveIncomeTaxRateReconciliationNOLDeferredAdjustmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "EffectiveIncomeTaxRateReconciliationNOLDeferredAdjustmentAmount", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Foreign NOL deferred adjustment, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to NOL deferred adjustment." } } }, "auth_ref": [] }, "pmi_EffectiveIncomeTaxRateReconciliationNOLDeferredAdjustmentPercent": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "EffectiveIncomeTaxRateReconciliationNOLDeferredAdjustmentPercent", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Foreign NOL deferred adjustment, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to NOL deferred adjustment." } } }, "auth_ref": [] }, "pmi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseConvertibleDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseConvertibleDebtAmount", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Non-deductible Convertible Note interest and debt discount amortization, amount", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for convertible debt." } } }, "auth_ref": [] }, "pmi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseConvertibleDebtPercent": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseConvertibleDebtPercent", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Non-deductible Convertible Note interest and debt discount amortization, percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for convertible debt." } } }, "auth_ref": [] }, "pmi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForeignAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForeignAmount", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Foreign Non-Deductible Items, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign nondeductible expenses." } } }, "auth_ref": [] }, "pmi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForeignPercent": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForeignPercent", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Foreign Non-Deductible Items, percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for foreign." } } }, "auth_ref": [] }, "pmi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIssuanceCostsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIssuanceCostsAmount", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Non-deductible issuance costs, amount", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for issuance costs." } } }, "auth_ref": [] }, "pmi_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIssuanceCostsPercent": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseIssuanceCostsPercent", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Non-deductible issuance costs, percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for issuance costs." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "terseLabel": "Other, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } }, "auth_ref": [ "r1078", "r1281", "r1288", "r1462", "r1463" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Incentive Stock based compensation, percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement." } } }, "auth_ref": [ "r1078", "r1281", "r1288", "r1462", "r1463" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments", "terseLabel": "Other, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1078", "r1281", "r1288", "r1462", "r1464" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Effects of deferred tax adjustments, net of federal benefits, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense." } } }, "auth_ref": [ "r1281", "r1288", "r1462", "r1464" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "State and local income taxes, net of federal benefit, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r536", "r1078", "r1281", "r1288", "r1462" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateReconciliationTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-and-income-loss-before-income-taxes-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation [Table]", "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation." } } }, "auth_ref": [ "r534", "r542", "r1078" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits", "negatedLabel": "Tax Credits, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": [ "r539", "r541", "r1281", "r1288", "r1462" ] }, "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmbeddedDerivativeFinancialInstrumentsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Embedded Derivative Financial Instruments [Member]", "documentation": "Derivative instrument embedded in host contract." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r506" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r506" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeStockOptionMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-valuation-assumptions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [ "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459" ] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntitiesTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine1", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressCityOrTown", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCentralIndexKey", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1167" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-document-and-entity-information", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-tables", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-valuation-assumptions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-tables", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-10q", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-and-income-loss-before-income-taxes-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-tables", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-10q", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-10q-tables", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-10q-details", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-tables", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-tables", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-tables", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details-parentheticals", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details-parentheticals", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-tables", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-tables", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-tables", "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-tables", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-tables", "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-tables", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-tables", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-tables", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-tables", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details", "http://picardmedical.com/20260331/role/statement-note-8-debt-tables", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-tables", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-reserved-common-stock-10q-details", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-reserved-common-stock-details", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-tables", "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1167" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityExTransitionPeriod", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r1180" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityFilerCategory", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1167" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityRegistrantName", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1167" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntitySmallBusiness", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1167" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1167" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquipmentMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [ "r1340", "r1341" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquityComponentDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r77", "r78", "r86", "r118", "r119", "r137", "r138", "r139", "r172", "r173", "r174", "r178", "r186", "r188", "r190", "r210", "r244", "r247", "r289", "r290", "r292", "r352", "r382", "r387", "r388", "r389", "r392", "r394", "r397", "r427", "r428", "r432", "r433", "r510", "r561", "r562", "r574", "r575", "r576", "r579", "r587", "r588", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r631", "r635", "r636", "r637", "r638", "r649", "r684", "r685", "r686", "r687", "r688", "r689", "r693", "r717", "r746", "r788", "r789", "r798", "r799", "r814", "r832", "r848", "r849", "r850", "r875", "r949", "r1372" ] }, "pmi_EquityFinancingGrossProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "EquityFinancingGrossProceeds", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_EquityFinancingGrossProceeds", "terseLabel": "Equity Financing, Gross Proceeds", "documentation": "The gross proceeds from the equity financing." } } }, "auth_ref": [] }, "pmi_EquityReceivedPreipoServices": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "EquityReceivedPreipoServices", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_EquityReceivedPreipoServices", "terseLabel": "Equity Received, Pre-IPO Services", "documentation": "The percent of equity receivable in return for pre-IPO services." } } }, "auth_ref": [] }, "pmi_EquityReceivedPreipoServicesConditionalAdditionalPercent": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "EquityReceivedPreipoServicesConditionalAdditionalPercent", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_EquityReceivedPreipoServicesConditionalAdditionalPercent", "terseLabel": "Equity Received, Pre-IPO Services, Conditional Additional Percent", "documentation": "The percent of equity receivable in return for pre-IPO services, if certain conditions are met." } } }, "auth_ref": [] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "EuropeMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Europe [Member]" } } }, "auth_ref": [ "r1590", "r1591", "r1592", "r1593" ] }, "pmi_ExistingWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ExistingWarrantsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "Existing Warrants [Member]", "documentation": "Represents existing warrants." } } }, "auth_ref": [] }, "pmi_ExternalFundingReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ExternalFundingReceived", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ExternalFundingReceived", "terseLabel": "External Funding Received", "documentation": "External Funding Received" } } }, "auth_ref": [] }, "us-gaap_ExtinguishmentOfDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ExtinguishmentOfDebtAmount", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ExtinguishmentOfDebtAmount", "terseLabel": "Extinguishment of Debt, Amount", "documentation": "Gross amount of debt extinguished." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r656", "r657", "r658", "r1079", "r1082", "r1118", "r1525" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-tables", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r656", "r657", "r1118" ] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-tables", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r672", "r674", "r1122", "r1123", "r1506", "r1508" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r336", "r438", "r439", "r440", "r441", "r442", "r443", "r452", "r453", "r652", "r653", "r655", "r656", "r657", "r658", "r665", "r666", "r668", "r672", "r731", "r732", "r733", "r738", "r1054", "r1055", "r1067", "r1068", "r1069", "r1070", "r1071", "r1115", "r1118", "r1122", "r1123" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r659", "r660", "r661", "r662", "r663", "r664", "r667" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r654", "r655", "r656", "r658", "r1115", "r1491", "r1503" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r336", "r438", "r443", "r452", "r655", "r666", "r672", "r731", "r1067", "r1068", "r1069", "r1070", "r1071", "r1115", "r1122", "r1123" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r336", "r438", "r443", "r452", "r454", "r655", "r656", "r666", "r672", "r732", "r1054", "r1055", "r1067", "r1068", "r1069", "r1070", "r1071", "r1115", "r1122", "r1123" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r336", "r438", "r439", "r440", "r441", "r442", "r443", "r452", "r453", "r655", "r656", "r657", "r658", "r666", "r672", "r733", "r1054", "r1055", "r1067", "r1068", "r1069", "r1070", "r1071", "r1115", "r1118", "r1122", "r1123" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r659", "r660", "r661", "r662", "r663", "r664", "r667" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details-parentheticals", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details-parentheticals" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": [ "r659", "r660", "r661", "r662", "r663", "r664", "r667" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r654", "r655", "r656", "r658", "r1115", "r1491", "r1503" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [ "r1499", "r1500" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r336", "r438", "r439", "r440", "r441", "r442", "r443", "r452", "r453", "r652", "r653", "r655", "r656", "r657", "r658", "r665", "r666", "r668", "r672", "r731", "r732", "r733", "r738", "r1054", "r1055", "r1067", "r1068", "r1069", "r1070", "r1071", "r1115", "r1118", "r1122", "r1123" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r1115", "r1488", "r1489", "r1490", "r1491", "r1492", "r1503" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r659", "r660", "r661", "r662", "r663", "r664", "r667" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-tables", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r659", "r664", "r667" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in fair value", "label": "Change in fair value", "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r660", "r667" ] }, "pmi_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossOnSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossOnSettlements", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Loss on settlement of debt", "label": "pmi_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossOnSettlements", "documentation": "Amount of gain (loss) on settlements of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues", "negatedLabel": "Initial fair value of derivative liabilities at issuance", "documentation": "Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r662", "r667" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Derecognition of derivative liability", "label": "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements", "negatedLabel": "Cash payments on Notes Payable", "documentation": "Amount of settlements of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r662", "r667" ] }, "pmi_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlementsThroughShareIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlementsThroughShareIssuance", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details" ], "lang": { "en-us": { "role": { "label": "pmi_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlementsThroughShareIssuance", "negatedLabel": "Settlement of Notes Payable via common share issuance", "documentation": "Represents the settlement through share issuance for fair value net derivative assets or liabilities measured on recurring basis with unobservable inputs." } } }, "auth_ref": [] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details" ], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Beginning balance", "negatedPeriodEndLabel": "Ending balance", "label": "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r659", "r667" ] }, "pmi_FairValueOfDerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "FairValueOfDerivativeLiabilities", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_FairValueOfDerivativeLiabilities", "terseLabel": "Fair Value of Derivative Liabilities", "documentation": "The fair value of derivative liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r1504" ] }, "pmi_FangFamilyFundILLCNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "FangFamilyFundILLCNoteMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Fang Family Fund I, LLC Note [Member]", "documentation": "Related to debt." } } }, "auth_ref": [] }, "pmi_FangFamilyFundILoan2Member": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "FangFamilyFundILoan2Member", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Fang Family Fund I Loan 2 [Member]", "documentation": "Represents information pertaining to the second Fang Family Fund I loan." } } }, "auth_ref": [] }, "pmi_FangFamilyFundILoanMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "FangFamilyFundILoanMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Fang Family Fund I Loan [Member]", "documentation": "Represents the loan from the Fang Family Fund I." } } }, "auth_ref": [] }, "pmi_FangFamilyFundIiLoan3Member": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "FangFamilyFundIiLoan3Member", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Fang Family Fund II Loan 3 [Member]", "documentation": "Represents Fang Family Fund II Loan 3." } } }, "auth_ref": [] }, "pmi_FangFamilyFundIiLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "FangFamilyFundIiLoanMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Fang Family Fund II Loan [Member]", "documentation": "Fang Family Fund II Loan" } } }, "auth_ref": [] }, "us-gaap_FederalMinistryOfFinanceGermanyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FederalMinistryOfFinanceGermanyMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details" ], "lang": { "en-us": { "role": { "label": "Federal Ministry of Finance, Germany [Member]", "documentation": "Designated tax department of the government of Germany." } } }, "auth_ref": [ "r1466", "r1470" ] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Present value of future minimum payments, finance lease", "label": "us-gaap_FinanceLeaseLiability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r695", "r707" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Current portion of finance lease liability", "negatedTerseLabel": "Current portion of lease liability, financing lease", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r695" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Finance lease liability, net of current portion", "terseLabel": "Lease liability, net of current portion, financing lease", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r695" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "terseLabel": "Present value of future minimum payments, financing lease", "totalLabel": "Undiscounted total, finance lease", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r707", "r1282", "r1291", "r1538" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details": { "parentTag": "pmi_FinanceLeaseLiabilityUndiscountedTotal", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2027, finance lease", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r707", "r1282", "r1291", "r1538" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2027, finance lease", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r707", "r1282", "r1291", "r1538" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details": { "parentTag": "pmi_FinanceLeaseLiabilityUndiscountedTotal", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "terseLabel": "2026 (nine months remaining), finance lease", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1518" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount", "negatedTerseLabel": "Less: imputed interest, finance lease", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r707" ] }, "pmi_FinanceLeaseLiabilityUndiscountedTotal": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "FinanceLeaseLiabilityUndiscountedTotal", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details" ], "lang": { "en-us": { "role": { "label": "pmi_FinanceLeaseLiabilityUndiscountedTotal", "totalLabel": "Undiscounted total, finance lease", "documentation": "Finance Lease, Liability, Undiscounted Total" } } }, "auth_ref": [] }, "pmi_FinanceLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "FinanceLeasePayments", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_FinanceLeasePayments", "terseLabel": "Finance Lease Payments", "documentation": "Payments on finance leases." } } }, "auth_ref": [] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeasePrincipalPayments", "negatedLabel": "Repayment of finance lease obligations", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r696", "r703" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Finance lease right-of-use assets, net", "terseLabel": "Finance lease right-of-use assets, net", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r694" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent", "terseLabel": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r706", "r1125" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1", "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term (Year)", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r705", "r1125" ] }, "pmi_FinanceLeasesForOfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "FinanceLeasesForOfficeEquipmentMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Finance Leases for Office Equipment [Member]", "documentation": "Represents the finance leases for office equipment." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q" ], "lang": { "en-us": { "role": { "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [ "r670" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)", "documentation": "Useful life of finite-lived intangible asset, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r281" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Finite-lived intangible assets, accumulated amortization", "documentation": "Amount of accumulated amortization of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r98", "r258", "r274", "r1007", "r1334" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details" ], "lang": { "en-us": { "role": { "label": "Thereafter", "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r1330" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r276", "r1007" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details" ], "lang": { "en-us": { "role": { "label": "2026 (nine months remaining)", "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in remainder of current fiscal year. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r1330" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details" ], "lang": { "en-us": { "role": { "label": "2030", "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r276", "r1007" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details" ], "lang": { "en-us": { "role": { "label": "2029", "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r276", "r1007" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details" ], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r276", "r1007" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of amortization expense for finite-lived intangible asset expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Excludes goodwill and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r276", "r1007" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived, Class [Axis]", "documentation": "Information by class of finite-lived intangible asset." } } }, "auth_ref": [ "r267", "r269", "r270", "r271", "r273", "r274", "r277", "r278", "r752", "r753", "r860", "r1004", "r1007", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1334", "r1595", "r1596", "r1597" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Finite-lived intangible assets, gross", "documentation": "Amount, before accumulated amortization, of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r258", "r274", "r753", "r1007", "r1334" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived, Class [Domain]", "documentation": "Class of finite-lived intangible asset." } } }, "auth_ref": [ "r267", "r269", "r270", "r271", "r273", "r274", "r277", "r278", "r860", "r1004", "r1007", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1334", "r1595", "r1596", "r1597" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Finite-lived intangible assets, net", "totalLabel": "Total", "documentation": "Amount, after accumulated amortization, of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed." } } }, "auth_ref": [ "r752", "r1328" ] }, "pmi_FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details" ], "lang": { "en-us": { "role": { "label": "pmi_FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour", "terseLabel": "Thereafter", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ForeignCountryMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction, Foreign [Member]", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": [ "r534", "r542" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r683" ] }, "pmi_ForgivenessOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ForgivenessOfRelatedPartyDebt", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ForgivenessOfRelatedPartyDebt", "terseLabel": "Forgiveness of Related Party Debt", "documentation": "The amount forgiven from the related party debt." } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [ "r1048", "r1340", "r1341" ] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Derivative loss", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": [ "r1479" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Loss on settlement of debt", "terseLabel": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on settlement of debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r5", "r20", "r21" ] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Geographic Concentration Risk [Member]", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r991", "r1304" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r91", "r97", "r260", "r788", "r789", "r790", "r1038", "r1044", "r1079", "r1080", "r1081", "r1111", "r1117", "r1134", "r1319", "r1320", "r1476" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r259", "r263", "r1044" ] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": [ "r266", "r279", "r281" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_GoodwillImpairmentLoss", "terseLabel": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r5", "r261", "r262", "r263", "r265", "r583", "r1044", "r1117" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_GrossProfit", "totalLabel": "Gross loss", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r32", "r34", "r161", "r163", "r164", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r393", "r682", "r1033", "r1037", "r1189", "r1190", "r1298", "r1307", "r1308", "r1309", "r1310", "r1317", "r1352" ] }, "pmi_HighTrailMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "HighTrailMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "High Trail [Member]", "documentation": "Related to High Trail." } } }, "auth_ref": [] }, "pmi_HunniwellDebtNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "HunniwellDebtNoteMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Hunniwell Debt Note [Member]", "documentation": "Represents the debt note from Hunniwell." } } }, "auth_ref": [] }, "pmi_HunniwellPicardILlcMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "HunniwellPicardILlcMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Hunniwell Picard I, LLC [Member]", "documentation": "Hunniwell Picard I, LLC" } } }, "auth_ref": [] }, "pmi_HunniwellTravelExpenseLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "HunniwellTravelExpenseLoanMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Hunniwell Travel Expense Loan [Member]", "documentation": "Hunniwell Travel Expense Loan" } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IPOMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse", "terseLabel": "Impairment, Long-Lived Asset, Held-for-Use", "documentation": "Amount of impairment loss for long-lived asset held and used. Includes, but is not limited to, impairment loss for long-lived asset to be disposed of other than by sale." } } }, "auth_ref": [ "r5", "r143", "r297", "r1021", "r1116", "r1337" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Long-Lived Asset, Excluding Intangible Asset and Goodwill, Impairment and Disposal [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r1342" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-and-income-loss-before-income-taxes-details": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-and-income-loss-before-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "terseLabel": "Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r161", "r165", "r533" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-and-income-loss-before-income-taxes-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-and-income-loss-before-income-taxes-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Loss before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r33", "r52", "r807", "r809", "r830", "r1008", "r1022", "r1024", "r1026", "r1033", "r1037", "r1298", "r1307", "r1308", "r1309", "r1310" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-and-income-loss-before-income-taxes-details": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-and-income-loss-before-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "terseLabel": "Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r161", "r165", "r533" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis] (Deprecated 2026)", "documentation": "Information by location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain] (Deprecated 2026)", "documentation": "Location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r157", "r534", "r542", "r547", "r557", "r1078", "r1470" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r157", "r534", "r542", "r547", "r557", "r1078", "r1470" ] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r547", "r1470" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [ "r547", "r1470" ] }, "us-gaap_IncomeTaxContingencyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxContingencyTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-10q", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Income Tax Contingency [Table]", "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r1465" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-10q" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r161", "r166", "r528", "r534", "r543", "r544", "r545", "r548", "r555", "r567", "r569", "r570", "r571", "r815", "r859", "r871", "r1078" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Provision (benefit) for income taxes", "totalLabel": "Income Tax Provision/(Benefit) and Effective Income Tax Rate, amount", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r60", "r68", "r161", "r189", "r190", "r209", "r225", "r235", "r532", "r534", "r568", "r836", "r1008", "r1022", "r1024", "r1026", "r1078" ] }, "us-gaap_IncomeTaxPaidFederalAfterRefundReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxPaidFederalAfterRefundReceived", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details": { "parentTag": "us-gaap_IncomeTaxesPaidNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details" ], "lang": { "en-us": { "role": { "label": "United States - Federal", "documentation": "Amount, after income tax refund received, of cash paid to federal (national) tax jurisdiction for tax on income." } } }, "auth_ref": [ "r157", "r556" ] }, "us-gaap_IncomeTaxPaidForeignAfterRefundReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxPaidForeignAfterRefundReceived", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details": { "parentTag": "us-gaap_IncomeTaxesPaidNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxPaidForeignAfterRefundReceived", "terseLabel": "Foreign", "documentation": "Amount, after income tax refund received, of cash paid to foreign tax jurisdiction for tax on income." } } }, "auth_ref": [ "r157", "r556" ] }, "us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxPaidStateAndLocalAfterRefundReceived", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details": { "parentTag": "us-gaap_IncomeTaxesPaidNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details" ], "lang": { "en-us": { "role": { "label": "United States - States", "documentation": "Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income." } } }, "auth_ref": [ "r157", "r556" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r136", "r530", "r531", "r548", "r549", "r554", "r559", "r865" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r540", "r1078", "r1462" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Effects of change in state tax rate, net of federal benefits, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r529", "r534", "r538", "r1078" ] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Foreign Rate Differential, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r537", "r542", "r1078", "r1462" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "U.S. Federal statutory income tax (benefit), amount", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r534", "r1078" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther", "terseLabel": "Other, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } }, "auth_ref": [ "r1078", "r1462", "r1463" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Incentive Stock based compensation, amount", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r1078", "r1462", "r1463" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxReconciliationOtherAdjustments", "terseLabel": "Other, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r1078", "r1462", "r1464" ] }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "Effects of deferred tax adjustments, net of federal benefits, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)." } } }, "auth_ref": [ "r1462", "r1464" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "State and local income taxes, net of federal benefit, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r536", "r1078", "r1462" ] }, "us-gaap_IncomeTaxReconciliationTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxReconciliationTaxCredits", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxReconciliationTaxCredits", "negatedLabel": "Tax Credits, amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": [ "r539", "r541", "r1462" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r43", "r1278", "r1468", "r1469" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxesPaidNet", "totalLabel": "Total Cash paid for income taxes, net of refunds", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r54", "r157", "r556", "r557" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedTerseLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Accrued expenses and other liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOperatingLeaseLiability", "terseLabel": "Operating lease obligation", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r1183", "r1274" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedTerseLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "documentation": "Amount, after accumulated amortization, of finite- and indefinite-lived intangible assets and capitalized cost for software to be sold, leased, or marketed. Excludes goodwill." } } }, "auth_ref": [ "r267", "r788", "r789", "r791", "r1328", "r1331" ] }, "pmi_InterestCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "InterestCostsIncurredDuringNoncashOrPartialNoncashTransaction", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Interest added to principal on convertible notes", "documentation": "The amount of interest costs that were incurred during a noncash or partial noncash transaction." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Interest expense", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": [ "r1037", "r1112", "r1228", "r1307" ] }, "us-gaap_InterestPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterestPaid", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_InterestPaid", "terseLabel": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities." } } }, "auth_ref": [ "r1277" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "terseLabel": "Interest Paid, Excluding Capitalized Interest, Operating Activity", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r151", "r153", "r156" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accrued interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r1013" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_InterestPayableCurrentAndNoncurrent", "terseLabel": "Interest Payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r1203", "r1529", "r1530", "r1532", "r1539" ] }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterimPeriodCostsNotAllocableDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "Interim Period, Costs Not Allocable [Domain]", "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred." } } }, "auth_ref": [ "r18" ] }, "us-gaap_InventoryAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryAdjustments", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_InventoryAdjustments", "negatedLabel": "Allowance for excess and obsolete inventory", "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods." } } }, "auth_ref": [ "r19", "r1195", "r1212" ] }, "us-gaap_InventoryCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryCurrentTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details" ], "lang": { "en-us": { "role": { "label": "Inventory, Current [Table]", "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1195", "r1208" ] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryGross", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_InventoryGross", "totalLabel": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r1195", "r1212" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Inventories, net", "terseLabel": "Inventory, Net", "totalLabel": "Inventories, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r89", "r128", "r1010", "r1134" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r61", "r85", "r89", "r127", "r254", "r255", "r257", "r750", "r1027" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details" ], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1195", "r1210" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details" ], "lang": { "en-us": { "role": { "label": "Work in process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r1195", "r1209" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Provision for excess and obsolete inventory", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r256" ] }, "pmi_IssuedAsConversionSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "IssuedAsConversionSharesMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Issued as Conversion Shares [Member]", "documentation": "Issued as Conversion Shares" } } }, "auth_ref": [] }, "pmi_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "LaboratoryEquipmentMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Laboratory Equipment [Member]", "documentation": "Laboratory Equipment." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LeaseContractualTermAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r709", "r1516" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LeaseContractualTermDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r709", "r1516" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-10q-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LeaseCost", "totalLabel": "Total operating lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r699", "r1125" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-tables", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-tables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1517" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r708", "r1340", "r1341" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "LegalEntityAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-document-and-entity-information", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-tables", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-valuation-assumptions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-tables", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-10q", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-and-income-loss-before-income-taxes-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-tables", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-10q", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-10q-tables", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-10q-details", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-tables", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-tables", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-tables", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details-parentheticals", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details-parentheticals", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-tables", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-tables", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-tables", "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-tables", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-tables", "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-tables", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-tables", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-tables", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-tables", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details", "http://picardmedical.com/20260331/role/statement-note-8-debt-tables", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-tables", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-reserved-common-stock-10q-details", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-reserved-common-stock-details", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-tables", "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r698" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "terseLabel": "Present value of future minimum payments, operating lease", "totalLabel": "Undiscounted total, operating lease", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r707", "r1282", "r1291", "r1538" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details": { "parentTag": "pmi_LesseeOperatingLeaseUndiscountedTotal", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2027, operating lease", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r707", "r1282", "r1291", "r1538" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2027, operating lease", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r707", "r1282", "r1291", "r1538" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details": { "parentTag": "pmi_LesseeOperatingLeaseUndiscountedTotal", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "terseLabel": "2026 (nine months remaining), operating lease", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1518" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedTerseLabel": "Less: imputed interest, operating lease", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r707" ] }, "pmi_LesseeOperatingLeaseUndiscountedTotal": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "LesseeOperatingLeaseUndiscountedTotal", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details" ], "lang": { "en-us": { "role": { "label": "pmi_LesseeOperatingLeaseUndiscountedTotal", "totalLabel": "Undiscounted total, operating lease", "documentation": "Lessee, Operating Lease, Undiscounted Total" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r80", "r81", "r161", "r163", "r164", "r243", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r393", "r591", "r592", "r593", "r682", "r904", "r1032", "r1058", "r1166", "r1214", "r1352", "r1520", "r1521" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities, temporary equity and stockholders\u2019 equity (deficit)", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r126", "r788", "r789", "r801", "r825", "r1134", "r1152", "r1153", "r1281", "r1286", "r1317", "r1510" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r80", "r81", "r84", "r104", "r161", "r163", "r164", "r243", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r393", "r591", "r592", "r593", "r682", "r1134", "r1352", "r1520", "r1521" ] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesFairValueDisclosure", "totalLabel": "Total", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r655", "r1488" ] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LicensingAgreementsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": [ "r527", "r1096", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1328", "r1331", "r1332", "r1333", "r1461" ] }, "us-gaap_LoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LoansPayableCurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Loans from related parties", "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r1200" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "LocalPhoneNumber", "presentation": [ "http://picardmedical.com/20260331/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-tables", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-tables" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Long-Lived Asset [Table Text Block]", "documentation": "Tabular disclosure of long-lived asset located in country of domicile and foreign country in which asset is held if it is not provided as part of reportable segment information. Long-lived asset excludes financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax asset. Includes, but is not limited to, subtotal of geographical information about group of countries." } } }, "auth_ref": [ "r1311" ] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongTermDebtFairValue", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Senior Secured Note (unpaid principal of $15,000)", "terseLabel": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [ "r1122", "r1123", "r1488", "r1490", "r1491", "r1492", "r1505", "r1506", "r1507", "r1509" ] }, "us-gaap_LossOnContractTermination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LossOnContractTermination", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_LossOnContractTermination", "terseLabel": "Loss on Contract Termination", "documentation": "The loss recognized on termination of a contract." } } }, "auth_ref": [ "r748" ] }, "pmi_LossOnContractTerminationMonthlyPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "LossOnContractTerminationMonthlyPayment", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_LossOnContractTerminationMonthlyPayment", "terseLabel": "Loss on Contract Termination, Monthly Payment", "documentation": "The monthly payment on the termination payable." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "MajorCustomersAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r240", "r1059", "r1062", "r1146", "r1150", "r1544", "r1545", "r1546", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1582", "r1583" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "MaximumMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r82", "r83", "r220", "r307", "r308", "r309", "r310", "r463", "r499", "r500", "r501", "r524", "r658", "r734", "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r747", "r844", "r845", "r858", "r896", "r897", "r957", "r960", "r964", "r965", "r975", "r985", "r986", "r988", "r989", "r1002", "r1003", "r1041", "r1073", "r1079", "r1082", "r1083", "r1118", "r1119", "r1120", "r1121", "r1147", "r1354", "r1360" ] }, "pmi_May2026PublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "May2026PublicOfferingMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "May 2026 Public Offering [Member]", "documentation": "Represents the May 2026 Public Offering." } } }, "auth_ref": [] }, "pmi_MeasurementInputCalibrationDiscountMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "MeasurementInputCalibrationDiscountMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Calibration Discount [Member]", "documentation": "Measurement input using a calibration discount." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r1079", "r1082", "r1083", "r1136", "r1490", "r1491", "r1492" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r498", "r1490", "r1491", "r1492" ] }, "pmi_MeasurementInputNoExerciseWindowMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "MeasurementInputNoExerciseWindowMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, No Exercise Window [Member]", "documentation": "Measurement input using the no exercise window." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r499", "r1118", "r1490", "r1491", "r1492" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r501", "r1490", "r1491", "r1492" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r497", "r498", "r499", "r500", "r501", "r502", "r656", "r657", "r658", "r1079", "r1082", "r1083", "r1118", "r1525" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r656", "r657", "r658", "r1079", "r1082", "r1083", "r1118", "r1525" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "MinimumMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r82", "r83", "r220", "r307", "r308", "r309", "r310", "r463", "r499", "r500", "r501", "r524", "r658", "r734", "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r747", "r844", "r845", "r858", "r896", "r897", "r957", "r960", "r964", "r965", "r975", "r985", "r986", "r988", "r989", "r1002", "r1003", "r1041", "r1073", "r1079", "r1082", "r1083", "r1118", "r1119", "r1120", "r1147", "r1354", "r1360" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners", "terseLabel": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_MinorityInterestOwnershipPercentageByParent", "terseLabel": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": [ "r240", "r1059", "r1062", "r1146", "r1150", "r1544", "r1545", "r1546", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1582", "r1583" ] }, "us-gaap_NatureOfExpenseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NatureOfExpenseAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "Nature of Expense [Axis]", "documentation": "Information by type of cost or expense." } } }, "auth_ref": [ "r18" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit." } } }, "auth_ref": [ "r152" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from investing activities:", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets." } } }, "auth_ref": [ "r152" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r41", "r42", "r44" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Net loss", "totalLabel": "Net loss", "terseLabel": "Net loss", "negatedTerseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r35", "r44", "r53", "r78", "r80", "r81", "r132", "r134", "r139", "r161", "r163", "r164", "r169", "r177", "r182", "r183", "r184", "r185", "r186", "r189", "r190", "r197", "r243", "r290", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r353", "r356", "r359", "r364", "r393", "r429", "r510", "r578", "r588", "r651", "r682", "r831", "r926", "r947", "r948", "r1022", "r1024", "r1026", "r1164", "r1352" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "totalLabel": "Net loss attributable to common stockholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r78", "r142", "r182", "r183", "r184", "r185", "r193", "r194", "r198", "r201", "r356", "r359", "r364", "r588" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-tables", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle." } } }, "auth_ref": [ "r73", "r74", "r75", "r76", "r77", "r78", "r148", "r149", "r150", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r184", "r191", "r208", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r350", "r351", "r352", "r353", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r508", "r509", "r510", "r511", "r561", "r562", "r563", "r564", "r565", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r584", "r585", "r586", "r587", "r588", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r669", "r712", "r713", "r714", "r715", "r716", "r717", "r746", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r863" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [ "r191" ] }, "us-gaap_NewJerseyDivisionOfTaxationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NewJerseyDivisionOfTaxationMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details" ], "lang": { "en-us": { "role": { "label": "New Jersey Division of Taxation [Member]", "documentation": "Designated tax department of the government of the state of New Jersey." } } }, "auth_ref": [ "r1466", "r1470" ] }, "pmi_NewWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "NewWarrantsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "New Warrants [Member]", "documentation": "Represents new warrants." } } }, "auth_ref": [] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NonUsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-details" ], "lang": { "en-us": { "role": { "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1590", "r1591", "r1592", "r1593" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities:" } } }, "auth_ref": [] }, "pmi_NoncontrollingOwnersMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "NoncontrollingOwnersMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Non-controlling Owners [Member]", "documentation": "Non-controlling Owners" } } }, "auth_ref": [] }, "us-gaap_NonmonetaryTransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NonmonetaryTransactionTypeAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Axis]", "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": [ "r710", "r711", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133" ] }, "us-gaap_NonmonetaryTransactionTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NonmonetaryTransactionTypeDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "Nonmonetary Transaction Type [Domain]", "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange." } } }, "auth_ref": [ "r710", "r711", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Other expense, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r37", "r1189", "r1190", "r1317" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Other income and (expense):" } } }, "auth_ref": [] }, "pmi_NonqualifiedVestedStockOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "NonqualifiedVestedStockOptionsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Non-qualified Vested Stock Options [Member]", "documentation": "Represents non-qualified vested stock options." } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NonrelatedPartyMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r1281", "r1289", "r1290" ] }, "pmi_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "us-gaap_NotesReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NotesReceivableGross", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NotesReceivableGross", "terseLabel": "Financing Receivable, before Allowance for Credit Loss", "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r55", "r56", "r71", "r72", "r88", "r120", "r241", "r242", "r252", "r253", "r671", "r788", "r789", "r802", "r984", "r1042", "r1043", "r1186", "r1318" ] }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NotesReceivableNet", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NotesReceivableNet", "terseLabel": "Financing Receivable, after Allowance for Credit Loss", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r253", "r914", "r1312", "r1522", "r1529", "r1530", "r1537", "r1542" ] }, "pmi_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NumberOfOperatingSegments", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r1038", "r1306" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NumberOfReportableSegments", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1034", "r1040", "r1306" ] }, "pmi_OfficeAndComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "OfficeAndComputerEquipmentMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Office and Computer Equipment [Member]", "documentation": "Office and Computer Equipment." } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OfficeEquipmentMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-details" ], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [ "r1340", "r1341" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [ "r1026", "r1189", "r1190", "r1317" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingExpensesAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Operating loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r1022", "r1026", "r1033", "r1189", "r1190", "r1298", "r1307", "r1308", "r1309", "r1310", "r1317" ] }, "pmi_OperatingLeaseAnnualRentIncrease": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "OperatingLeaseAnnualRentIncrease", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_OperatingLeaseAnnualRentIncrease", "terseLabel": "Operating Lease, Annual Rent Increase", "documentation": "The annual percent increase in rent." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 }, "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-10q-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseCost", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r700", "r1125" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Present value of future minimum payments, operating lease", "label": "us-gaap_OperatingLeaseLiability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r695" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Current portion of operating lease liability", "negatedTerseLabel": "Current portion of lease liability, operating lease", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r695", "r1012" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Operating lease liability, net of current portion", "terseLabel": "Lease liability, net of current portion, operating lease", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r695" ] }, "pmi_OperatingLeaseMonthlyPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "OperatingLeaseMonthlyPayments", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_OperatingLeaseMonthlyPayments", "terseLabel": "Operating Lease, Monthly Payments", "documentation": "The monthly payment amount for the operating lease." } } }, "auth_ref": [] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeasePayments", "terseLabel": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r697", "r703" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets, net", "terseLabel": "Operating lease right-of-use assets, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r694" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Amortization of right of use asset", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1275" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r706", "r1125" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r705", "r1125" ] }, "pmi_OperatingLossCarryforwardLimitationOnTaxableIncomePercent": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "OperatingLossCarryforwardLimitationOnTaxableIncomePercent", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_OperatingLossCarryforwardLimitationOnTaxableIncomePercent", "terseLabel": "Operating Loss Carryforward, Limitation on Taxable Income, Percent", "documentation": "The percent of operating loss carryforward that is limited on taxable income." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r558" ] }, "pmi_OperatingLossCarryforwardsSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "OperatingLossCarryforwardsSubjectToExpiration", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_OperatingLossCarryforwardsSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards, Subject to Expiration", "documentation": "Amount of operating loss carryforward, before tax effects, that is subject to expiration." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Other accrued liabilities", "totalLabel": "Total other accrued liabilities, current portion", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1200" ] }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent", "totalLabel": "Total current and noncurrent other accrued liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other." } } }, "auth_ref": [ "r1529", "r1530", "r1532" ] }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherAccruedLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Other liabilities, noncurrent portion", "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1203" ] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherCommitmentsTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-tables", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-tables" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustments, net of tax", "terseLabel": "Translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r3", "r7", "r51" ] }, "pmi_OtherForeignCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "OtherForeignCountriesMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Other Foreign Countries [Member]", "documentation": "Other Foreign Countries." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Other liabilities, current portion", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r92", "r100", "r103", "r1134" ] }, "pmi_OtherStateTaxAgenciesMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "OtherStateTaxAgenciesMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details" ], "lang": { "en-us": { "role": { "label": "Other State Tax Agencies [Member]", "documentation": "Related to other state tax agencies." } } }, "auth_ref": [] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OverAllotmentOptionMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "OwnershipAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [ "r392", "r394" ] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "OwnershipDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [ "r392", "r394" ] }, "pmi_PaymentInKindOfNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "PaymentInKindOfNotesPayableMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Payment in Kind of Notes Payable [Member]", "documentation": "Payment in Kind of Notes Payable" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "terseLabel": "Payments of Debt Issuance Costs", "negatedLabel": "Financing costs paid", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r17" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfStockIssuanceCosts", "terseLabel": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r16" ] }, "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "terseLabel": "Payments to Acquire Interest in Subsidiaries and Affiliates", "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity)." } } }, "auth_ref": [ "r14" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchase of plant, property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r39" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q" ], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r434", "r436", "r437", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r457", "r458", "r459", "r1071" ] }, "pmi_PicardMedicalMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "PicardMedicalMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Picard Medical [Member]", "documentation": "Picard Medical" } } }, "auth_ref": [] }, "pmi_PlacementAgentMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "PlacementAgentMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Placement Agent [Member]", "documentation": "Represents the Placement Agent." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PlanNameAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PlanNameDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1434", "r1435", "r1436", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1455", "r1456", "r1457", "r1458", "r1459" ] }, "pmi_PolicyTable": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "PolicyTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "pmi_PolicyTable" } } }, "auth_ref": [] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PolicyTextBlockAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "pmi_PreIPOSubscriptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "PreIPOSubscriptionsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Pre-IPO Subscriptions [Member]", "documentation": "Represents information pertaining to pre-IPO subscriptions." } } }, "auth_ref": [] }, "pmi_PreferredStockConversionToCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "PreferredStockConversionToCommonStockMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Conversion to Common Stock [Member]", "documentation": "Related to stock conversion." } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockConvertibleSharesIssuable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockConvertibleSharesIssuable", "terseLabel": "Preferred Stock, Convertible, Shares Issuable (in shares)", "documentation": "Number of common shares issuable upon conversion of preferred stock." } } }, "auth_ref": [ "r371" ] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockDividendRatePercentage", "terseLabel": "Preferred Stock, Dividend Rate, Percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r370", "r958", "r961", "r963", "r976" ] }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockDividendsIncomeStatementImpact", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockDividendsIncomeStatementImpact", "negatedLabel": "Undeclared Series A-1 preferred dividends", "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders." } } }, "auth_ref": [ "r202" ] }, "us-gaap_PreferredStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockDividendsPerShareDeclared", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PreferredStockDividendsPerShareDeclared", "terseLabel": "Preferred Stock, Dividends Per Share, Declared (in dollars per share)", "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding." } } }, "auth_ref": [ "r392", "r394" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r86", "r118", "r387", "r388", "r397", "r788", "r789", "r798", "r1155", "r1156", "r1159", "r1160", "r1161", "r1162", "r1584", "r1588" ] }, "pmi_PreferredStockOriginalIssuePrice": { "xbrltype": "perShareItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "PreferredStockOriginalIssuePrice", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_PreferredStockOriginalIssuePrice", "terseLabel": "Preferred Stock, Original Issue Price (in dollars per share)", "documentation": "Preferred Stock, Original Issue Price" } } }, "auth_ref": [] }, "pmi_PrefundedWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "PrefundedWarrantMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "Pre-funded Warrant [Member]", "documentation": "Represents Pre-funded Warrant." } } }, "auth_ref": [] }, "pmi_PreipoFinancingCapitalRaised": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "PreipoFinancingCapitalRaised", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_PreipoFinancingCapitalRaised", "terseLabel": "Pre-IPO Financing Capital Raised", "documentation": "Pre-IPO Financing Capital Raised" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1213" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r1188" ] }, "pmi_ProbabilityChangeOfControlPercent": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ProbabilityChangeOfControlPercent", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Change of Control", "documentation": "The percent chance that a change of control will occur." } } }, "auth_ref": [] }, "pmi_ProbabilityMaturityPercent": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ProbabilityMaturityPercent", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Maturity", "documentation": "The percent chance that maturity will occur." } } }, "auth_ref": [] }, "pmi_ProbabilityQualifiedFinancingPercent": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ProbabilityQualifiedFinancingPercent", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Qualified Financing", "documentation": "The percent chance that qualified financing will occur." } } }, "auth_ref": [] }, "pmi_ProbabilitySuccessfulFinancingOrIpoPercent": { "xbrltype": "percentItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ProbabilitySuccessfulFinancingOrIpoPercent", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Successful financing/IPO", "documentation": "The percent chance that successful financing or an IPO will occur." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of convertible notes", "negatedTerseLabel": "Issuance of convertible notes", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of Common Stock", "terseLabel": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfDebt", "terseLabel": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r1272" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity", "terseLabel": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r2", "r866" ] }, "pmi_ProceedsFromIssuanceOrSaleOfEquityGross": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ProceedsFromIssuanceOrSaleOfEquityGross", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ProceedsFromIssuanceOrSaleOfEquityGross", "terseLabel": "Proceeds from Issuance or Sale of Equity, Gross", "documentation": "Proceeds from Issuance or Sale of Equity, Gross" } } }, "auth_ref": [] }, "pmi_ProceedsFromIssuanceOrSaleOfEquityNet": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ProceedsFromIssuanceOrSaleOfEquityNet", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_ProceedsFromIssuanceOrSaleOfEquityNet", "terseLabel": "Proceeds from Issuance or Sale of Equity, Net", "documentation": "The amount of cash inflow from the issuance or sale of equity, net of costs." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from notes payable", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from loans from related parties", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt", "terseLabel": "Proceeds from (Repayments of) Related Party Debt", "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Stock option exercise", "terseLabel": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r10" ] }, "pmi_ProceedsFromSubscriptionOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ProceedsFromSubscriptionOfCommonStock", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Proceeds from subscription of Common Stock", "documentation": "The cash inflow from subscriptions of common stock." } } }, "auth_ref": [] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details" ], "lang": { "en-us": { "role": { "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r1302" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProductMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r1021", "r1026", "r1059", "r1060" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ProductOrServiceAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r237", "r751", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r1005", "r1021", "r1024", "r1026", "r1059", "r1060", "r1145", "r1147", "r1148", "r1151", "r1154", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1268", "r1269", "r1270", "r1271", "r1350", "r1351", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ProductsAndServicesDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r237", "r751", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r1005", "r1021", "r1024", "r1026", "r1059", "r1060", "r1145", "r1147", "r1148", "r1151", "r1154", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1268", "r1269", "r1270", "r1271", "r1350", "r1351", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1582", "r1583" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Asset, Class [Axis]", "documentation": "Information by class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset." } } }, "auth_ref": [ "r294", "r295", "r708", "r1045", "r1046", "r1047", "r1048", "r1334", "r1335", "r1526" ] }, "us-gaap_PropertyPlantAndEquipmentDisposals": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentDisposals", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PropertyPlantAndEquipmentDisposals", "terseLabel": "Property, Plant and Equipment, Disposals", "documentation": "Amount of decrease in property, plant, and equipment from disposition. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r1338" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment, gross", "documentation": "Amount, before accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r90", "r95", "r294", "r829", "r1334" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Property and equipment, net", "terseLabel": "Property and equipment, net", "documentation": "Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r708", "r788", "r789", "r804", "r812", "r813", "r829", "r1134", "r1340" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment [Policy Text Block]", "documentation": "Disclosure of accounting policy for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r64", "r66", "r296", "r298", "r827", "r1334" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-tables", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-tables" ], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment [Table Text Block]", "documentation": "Tabular disclosure of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r1338" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Asset, Class [Domain]", "documentation": "Class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset." } } }, "auth_ref": [ "r294", "r295", "r708", "r1045", "r1046", "r1047", "r1048", "r1334", "r1335", "r1526" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property and equipment, useful life (Year)", "documentation": "Useful life of property, plant, and equipment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r1336" ] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PurchaseObligation", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_PurchaseObligation", "terseLabel": "Purchase Obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } }, "auth_ref": [ "r1282", "r1291", "r1538" ] }, "country_RS": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2026", "localname": "RS", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual" ], "lang": { "en-us": { "role": { "label": "SERBIA" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RangeAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r82", "r83", "r220", "r307", "r308", "r309", "r310", "r436", "r463", "r499", "r500", "r501", "r507", "r524", "r658", "r734", "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r744", "r747", "r844", "r845", "r858", "r896", "r897", "r957", "r960", "r964", "r965", "r975", "r985", "r986", "r988", "r989", "r1002", "r1003", "r1041", "r1073", "r1079", "r1082", "r1083", "r1118", "r1119", "r1120", "r1121", "r1147", "r1157", "r1347", "r1354", "r1360", "r1491" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RangeMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r82", "r83", "r220", "r307", "r308", "r309", "r310", "r436", "r463", "r499", "r500", "r501", "r507", "r524", "r658", "r734", "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r744", "r747", "r844", "r845", "r858", "r896", "r897", "r957", "r960", "r964", "r965", "r975", "r985", "r986", "r988", "r989", "r1002", "r1003", "r1041", "r1073", "r1079", "r1082", "r1083", "r1118", "r1119", "r1120", "r1121", "r1147", "r1157", "r1347", "r1354", "r1360", "r1491" ] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ReceivableTypeDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Receivable [Domain]", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": [ "r1315" ] }, "pmi_ReclassificationOfPlantPropertyAndEquipmentFromRightOfUseAssetsAcquiredUnderOperatingLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ReclassificationOfPlantPropertyAndEquipmentFromRightOfUseAssetsAcquiredUnderOperatingLeases", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Reclassification of plant, property and equipment from right of use assets acquired under operating leases", "documentation": "The amount of reclassification of plant, property and equipment from right of use assets acquired under operating leases." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r92", "r93", "r100", "r110", "r112", "r161", "r168", "r169", "r241", "r445", "r455", "r721", "r722", "r788", "r789", "r793", "r794", "r795", "r802", "r819", "r826", "r899", "r900", "r901", "r902", "r903", "r924", "r956", "r1011", "r1587", "r1594" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r92", "r93", "r100", "r110", "r112", "r161", "r168", "r169", "r721", "r722", "r723", "r724", "r788", "r789", "r795", "r819", "r826", "r899", "r900", "r901", "r902", "r903", "r924", "r956" ] }, "pmi_RelatedPartyNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "RelatedPartyNoteMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party Note [Member]", "documentation": "Related to related party note." } } }, "auth_ref": [] }, "pmi_RelatedPartyNoteReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "RelatedPartyNoteReceivableMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party Note Receivable [Member]", "documentation": "Related to related party note receivable." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r92", "r93", "r100", "r110", "r112", "r161", "r168", "r169", "r241", "r445", "r455", "r721", "r722", "r788", "r789", "r793", "r794", "r795", "r802", "r819", "r826", "r899", "r900", "r901", "r902", "r903", "r924", "r956", "r1011", "r1519", "r1587", "r1594" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r718", "r719", "r720", "r722", "r725", "r788", "r789", "r803", "r872", "r873", "r874", "r932", "r933", "r934", "r953", "r955" ] }, "pmi_RelatedPartyWorkingCapitalLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "RelatedPartyWorkingCapitalLoanMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party Working Capital Loan [Member]", "documentation": "Related Party Working Capital Loan" } } }, "auth_ref": [] }, "pmi_RelatedServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "RelatedServicesMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Services [Member]", "documentation": "Related Services." } } }, "auth_ref": [] }, "pmi_RentalsMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "RentalsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Rentals [Member]", "documentation": "Revenue generated from rentals." } } }, "auth_ref": [] }, "pmi_RepaymentOfRelatedPartyLoanThroughSettlementOfRelatedPartyReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "RepaymentOfRelatedPartyLoanThroughSettlementOfRelatedPartyReceivable", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Repayment of related party loan through settlement of related party receivable", "documentation": "Amount of repayment of related party loan through settlement of related party receivable in noncash transaction." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfConvertibleDebt", "terseLabel": "Repayments of Convertible Debt", "negatedLabel": "Repayment of convertible notes", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r40" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfDebt", "terseLabel": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r1273" ] }, "pmi_RepaymentsOfDebtInStockShares": { "xbrltype": "sharesItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "RepaymentsOfDebtInStockShares", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_RepaymentsOfDebtInStockShares", "terseLabel": "Repayments of Debt in Stock, Shares (in shares)", "documentation": "The number of shares used in the repayments of debt in stock." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_RepaymentsOfRelatedPartyDebt", "negatedLabel": "Payments to loans from related parties", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": [ "r40" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r161", "r170", "r171", "r326", "r373", "r724", "r730", "r745", "r817", "r1015", "r1017", "r1018", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1222", "r1223", "r1480", "r1481", "r1482", "r1483", "r1523", "r1524" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r526", "r1004", "r1022", "r1023", "r1037", "r1527" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member] (Deprecated 2026)", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r525" ] }, "pmi_ResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ResearchAndDevelopmentMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-10q-details" ], "lang": { "en-us": { "role": { "label": "Research and Development [Member]", "documentation": "Represents research and development." } } }, "auth_ref": [] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestrictedCash", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_RestrictedCash", "terseLabel": "Restricted Cash", "periodEndLabel": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r154", "r158", "r1198", "r1528", "r1529", "r1530", "r1531", "r1541" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r154", "r158", "r1198" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r122", "r124", "r390", "r788", "r789", "r800", "r824", "r852", "r857", "r870", "r907", "r1134" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RetainedEarningsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r77", "r78", "r172", "r173", "r174", "r178", "r186", "r188", "r190", "r244", "r247", "r289", "r290", "r292", "r352", "r387", "r397", "r427", "r428", "r432", "r433", "r510", "r561", "r562", "r574", "r575", "r576", "r579", "r587", "r588", "r622", "r623", "r624", "r625", "r627", "r628", "r631", "r649", "r693", "r746", "r814", "r848", "r850", "r875", "r1366", "r1368", "r1588" ] }, "us-gaap_RetirementPlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RetirementPlanNameAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Axis]", "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r1073", "r1182", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433" ] }, "us-gaap_RetirementPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RetirementPlanNameDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-details-textual" ], "lang": { "en-us": { "role": { "label": "Retirement Plan Name [Domain]", "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans." } } }, "auth_ref": [ "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r1073", "r1182", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1381", "r1382", "r1383", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1421", "r1422", "r1423", "r1424", "r1425", "r1426", "r1427", "r1428", "r1429", "r1430", "r1431", "r1432", "r1433" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Revenues", "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r209", "r222", "r223", "r233", "r235", "r237", "r238", "r240", "r420", "r421", "r422", "r751", "r1022", "r1026" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r69", "r410", "r412", "r413", "r414", "r415", "r416", "r418", "r419", "r422", "r424" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r928" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_RevenueRemainingPerformanceObligation", "terseLabel": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r65" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-tables", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-tables" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [ "r417" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenuesAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Revenues, net:" } } }, "auth_ref": [] }, "pmi_ReverseStockSplitMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ReverseStockSplitMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-details-textual" ], "lang": { "en-us": { "role": { "label": "Reverse Stock Split [Member]", "documentation": "A reverse stock split." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Right of use assets acquired under finance leases", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r704", "r1125", "r1279" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Right of use assets acquired under operating leases", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r704", "r1125", "r1279" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "pmi_SaleToThreeInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SaleToThreeInvestorsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Sale to Three Investors [Member]", "documentation": "Sale to Three Investors" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SalesRevenueNetMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r240", "r1301", "r1302" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-tables", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-10q-details", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r203" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-10q-tables", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r1297" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r1472" ] }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-tables", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangement with Individual, Share-Based Payment [Table]", "documentation": "Disclosure of information about equity-based arrangements (such as stock or unit options and stock or unit awards) with individual employees, which are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability." } } }, "auth_ref": [ "r22", "r27", "r47" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1467" ] }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-10q", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-10q-tables", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-tables" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]", "documentation": "Disclosure of information about diluted earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": [ "r195", "r196", "r199", "r201" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r535", "r1078", "r1462" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-tables", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r28" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-tables", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1488", "r1489" ] }, "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-tables", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-tables" ], "lang": { "en-us": { "role": { "label": "Fair Value, off-Balance-Sheet Risk [Table]", "documentation": "Disclosure of information about fair value of financial asset and liability not recognized in financial statement because of failure to meet criterion for recognition." } } }, "auth_ref": [ "r673", "r816", "r1505" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes goodwill." } } }, "auth_ref": [ "r267", "r274", "r277", "r278", "r280", "r752", "r1004", "r1007", "r1084", "r1085", "r1086", "r1087", "r1088", "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1334", "r1595", "r1596", "r1597" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-tables", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-tables" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived [Table Text Block]", "documentation": "Tabular disclosure of finite-lived intangible asset. Excludes goodwill." } } }, "auth_ref": [ "r1007", "r1327" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r1281", "r1287" ] }, "pmi_ScheduleOfIncomeTaxesPaidTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ScheduleOfIncomeTaxesPaidTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Income Taxes Paid [Table Text Block]", "documentation": "Tabular disclosure for income taxes paid." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-tables", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r1211" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment [Table]", "documentation": "Disclosure of information about property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r294", "r295", "r708", "r1045", "r1046", "r1047", "r1048", "r1334", "r1335", "r1526" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r161", "r168", "r169", "r721", "r722", "r724", "r788", "r789", "r793", "r794", "r795", "r802", "r930", "r931", "r934", "r1594" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r470", "r472", "r474", "r475", "r476", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r497", "r498", "r499", "r500", "r501", "r502", "r507" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-tables", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r8", "r9", "r48" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-tables", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r50" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-tables", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-tables" ], "lang": { "en-us": { "role": { "label": "Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of estimated amortization expense for finite-lived intangible asset and capitalized cost for software to be sold, leased, or marketed, expected to be recognized for each of five succeeding fiscal years. Excludes goodwill." } } }, "auth_ref": [ "r1007", "r1330" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-tables", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-tables" ], "lang": { "en-us": { "role": { "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r1300", "r1305" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "SegmentGeographicalDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-details" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r216", "r238", "r239", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r807", "r808", "r809", "r810", "r890", "r892", "r894", "r959", "r962", "r966", "r977", "r985", "r987", "r988", "r989", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1006", "r1029", "r1059", "r1061", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1149", "r1157", "r1544", "r1545", "r1546", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1582", "r1583" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r236", "r238", "r1035", "r1036", "r1039" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r36", "r1021", "r1022", "r1023", "r1026", "r1267" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-details" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member] (Deprecated 2026)", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "pmi_SellingGeneralAndAdministrativeMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SellingGeneralAndAdministrativeMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-10q-details" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative [Member]", "documentation": "Represents selling, general and administrative." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SeniorNotesCurrent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Senior secured note", "documentation": "Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment." } } }, "auth_ref": [ "r1134", "r1200" ] }, "pmi_SeniorSecuredNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SeniorSecuredNoteMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details-parentheticals", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details" ], "lang": { "en-us": { "role": { "label": "Senior Secured Note [Member]", "documentation": "Related to senior secured note." } } }, "auth_ref": [] }, "pmi_SeriesA1PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SeriesA1PreferredStockMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Series A1 Preferred Stock [Member]", "documentation": "Series A1 Preferred Stock" } } }, "auth_ref": [] }, "pmi_SeriesACommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SeriesACommonWarrantsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "Series A Common Warrants [Member]", "documentation": "Represents the Series A Common Warrants." } } }, "auth_ref": [] }, "pmi_SeriesBCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SeriesBCommonWarrantsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "Series B Common Warrants [Member]", "documentation": "Represents the Series B Common Warrants." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r1074" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-valuation-assumptions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details" ], "lang": { "en-us": { "role": { "label": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r500" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Expected stock price volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r499" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details" ], "lang": { "en-us": { "role": { "label": "Expected stock price volatility, maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r499" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details" ], "lang": { "en-us": { "role": { "label": "Expected stock price volatility, minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r499" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-valuation-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r501" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate, maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r501" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate, minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r501" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1076" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "periodStartLabel": "Beginning balance, available for grant (in shares)", "periodEndLabel": "Ending balance, available for grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedTerseLabel": "Forfeited, outstanding (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r484", "r1193", "r1206", "r1207", "r1364", "r1365" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r482", "r1193", "r1206", "r1207", "r1364", "r1365" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)", "periodStartLabel": "Beginning balance, outstanding (in shares)", "periodEndLabel": "Ending balance, outstanding (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r478", "r479" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)", "periodStartLabel": "Beginning balance, weighted average exercise price (in dollars per share)", "periodEndLabel": "Ending balance, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r478", "r479" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-valuation-assumptions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r474", "r475", "r476", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r498", "r499", "r500", "r501", "r502" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r483" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "terseLabel": "Forfeited, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r484" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r482" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r469", "r477", "r496", "r497", "r498", "r499", "r502", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharePrice", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-valuation-assumptions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details" ], "lang": { "en-us": { "role": { "label": "Stock Price (in dollars per share)", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)", "documentation": "Period from grant to expiration date of share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1075" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-valuation-assumptions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details" ], "lang": { "en-us": { "role": { "label": "Expected term (years) (Year)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r498" ] }, "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details" ], "lang": { "en-us": { "role": { "label": "Approved pool increase (in shares)", "documentation": "The amount of shares increased for the share based compensation plan." } } }, "auth_ref": [] }, "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantCanceled": { "xbrltype": "sharesItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantCanceled", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details" ], "lang": { "en-us": { "role": { "label": "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantCanceled", "terseLabel": "Cancelled, available for grant (in shares)", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant, Canceled" } } }, "auth_ref": [] }, "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantExercised": { "xbrltype": "sharesItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantExercised", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details" ], "lang": { "en-us": { "role": { "label": "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantExercised", "terseLabel": "Exercised, available for grant (in shares)", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant, Exercised." } } }, "auth_ref": [] }, "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantForfeited", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details" ], "lang": { "en-us": { "role": { "label": "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantForfeited", "terseLabel": "Forfeited, available for grant (in shares)", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant, Forfeited" } } }, "auth_ref": [] }, "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGranted": { "xbrltype": "sharesItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGranted", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details" ], "lang": { "en-us": { "role": { "label": "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGranted", "negatedTerseLabel": "Granted, available for grant (in shares)", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant, Granted" } } }, "auth_ref": [] }, "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledInPeriod", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details" ], "lang": { "en-us": { "role": { "label": "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledInPeriod", "negatedTerseLabel": "Cancelled, outstanding (in shares)", "documentation": "Share-based Compensation by Share-based Payment Award, Options, Cancelled in Period" } } }, "auth_ref": [] }, "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details" ], "lang": { "en-us": { "role": { "label": "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice", "terseLabel": "Cancelled, weighted average exercise price (in dollars per share)", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancelled in Period, Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)", "documentation": "Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r49" ] }, "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodTotalIntrinsicValue", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Total Intrinsic Value", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Total Intrinsic Value" } } }, "auth_ref": [] }, "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Weighted Average Exercise Price (in dollars per share)", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Weighted Average Exercise Price" } } }, "auth_ref": [] }, "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodWeightedAverageRemainingContractualTerm", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodWeightedAverageRemainingContractualTerm", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Weighted Average Remaining Contractual Term (Year)", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)", "documentation": "Number of options vested." } } }, "auth_ref": [ "r1460" ] }, "pmi_SharesIssuableUponConversionOfPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SharesIssuableUponConversionOfPreferredStockMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-10q-details", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details" ], "lang": { "en-us": { "role": { "label": "Shares Issuable Upon Conversion of Preferred Stock [Member]", "documentation": "Shares Issuable Upon Conversion of Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharesOutstanding", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balances (in shares)", "periodEndLabel": "Balances (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [ "r1361", "r1366", "r1368" ] }, "pmi_ShippingAndHandlingFeesAndCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "ShippingAndHandlingFeesAndCostsPolicyTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Shipping and Handling Fees and Costs [Policy Text Block]", "documentation": "Policy on shipping and handling fees and costs." } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 }, "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-10q-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_ShortTermLeaseCost", "terseLabel": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r701", "r1125" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r159", "r160" ] }, "pmi_SindexSsiFinancingLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SindexSsiFinancingLlcMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Sindex SSI Financing, LLC [Member]", "documentation": "Sindex SSI Financing, LLC" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction, Domestic State and Local [Member]", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": [ "r534" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementClassOfStockAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-reserved-common-stock-10q-details", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-reserved-common-stock-details" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r70", "r86", "r87", "r114", "r115", "r116", "r117", "r118", "r119", "r161", "r164", "r195", "r196", "r199", "r201", "r211", "r212", "r243", "r313", "r315", "r316", "r317", "r320", "r321", "r354", "r355", "r357", "r358", "r360", "r363", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r376", "r379", "r382", "r383", "r384", "r385", "r386", "r388", "r389", "r392", "r393", "r394", "r682", "r788", "r789", "r797", "r798", "r799", "r814", "r866", "r867", "r868", "r869", "r875", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r906", "r927", "r949", "r978", "r979", "r980", "r981", "r982", "r1181", "r1283", "r1285", "r1296", "r1367", "r1372" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r77", "r78", "r86", "r118", "r119", "r137", "r138", "r139", "r172", "r173", "r174", "r178", "r186", "r188", "r190", "r210", "r244", "r247", "r289", "r290", "r292", "r352", "r382", "r387", "r388", "r389", "r392", "r394", "r397", "r427", "r428", "r432", "r433", "r510", "r561", "r562", "r574", "r575", "r576", "r579", "r587", "r588", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r631", "r635", "r636", "r637", "r638", "r649", "r684", "r685", "r686", "r687", "r688", "r689", "r693", "r717", "r746", "r788", "r789", "r798", "r799", "r814", "r832", "r848", "r849", "r850", "r875", "r949", "r1372" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "StatementGeographicalAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-details" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r216", "r238", "r239", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r807", "r808", "r809", "r810", "r890", "r892", "r894", "r959", "r962", "r966", "r977", "r985", "r987", "r988", "r989", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1006", "r1029", "r1059", "r1061", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1149", "r1157", "r1544", "r1545", "r1546", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1582", "r1583" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementLineItems", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-tables", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-valuation-assumptions-details", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-tables", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-valuation-assumptions-10q-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-10q", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-and-income-loss-before-income-taxes-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-tables", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-10q", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-10q-tables", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-10q-details", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-tables", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-13-retirement-plans-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-tables", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-tables", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details-parentheticals", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details-parentheticals", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-tables", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-tables", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-inventory-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-tables", "http://picardmedical.com/20260331/role/statement-note-5-revenue", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-tables", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-tables", "http://picardmedical.com/20260331/role/statement-note-6-concentrations", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-tables", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-details-textual", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-concentration-risks-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-tables", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-tables", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-tables", "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details", "http://picardmedical.com/20260331/role/statement-note-8-debt-tables", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-tables", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-reserved-common-stock-10q-details", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-reserved-common-stock-details", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-tables", "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r86", "r87", "r92", "r93", "r100", "r110", "r112", "r114", "r117", "r118", "r119", "r124", "r172", "r173", "r174", "r210", "r354", "r355", "r357", "r360", "r366", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r394", "r396", "r397", "r407", "r693", "r751", "r788", "r789", "r797", "r798", "r799", "r864", "r876", "r887", "r898", "r899", "r900", "r901", "r902", "r903", "r906", "r909", "r910", "r911", "r912", "r913", "r915", "r916", "r917", "r918", "r920", "r921", "r922", "r923", "r924", "r928", "r929", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r949", "r1011", "r1024", "r1026", "r1158", "r1587" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r79", "r86", "r87", "r92", "r93", "r100", "r110", "r112", "r114", "r117", "r118", "r119", "r124", "r172", "r173", "r174", "r210", "r241", "r354", "r355", "r357", "r360", "r366", "r382", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r394", "r396", "r397", "r407", "r693", "r751", "r788", "r789", "r797", "r798", "r799", "r814", "r864", "r876", "r887", "r898", "r899", "r900", "r901", "r902", "r903", "r906", "r909", "r910", "r911", "r912", "r913", "r915", "r916", "r917", "r918", "r920", "r921", "r922", "r923", "r924", "r928", "r929", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r949", "r1011", "r1024", "r1026", "r1158", "r1587" ] }, "pmi_StockCancelledDuringThePeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "StockCancelledDuringThePeriodShares", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "pmi_StockCancelledDuringThePeriodShares", "terseLabel": "Common Stock cancellation (in shares)", "documentation": "The number of shares of stock cancelled during the period." } } }, "auth_ref": [] }, "pmi_StockCancelledDuringThePeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "StockCancelledDuringThePeriodValue", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "pmi_StockCancelledDuringThePeriodValue", "terseLabel": "Common Stock cancellation", "documentation": "The amount of stock cancelled during the period." } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Conversion of convertible note and accrued interest to common stock", "terseLabel": "Stock Issued", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r1279" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Common Stock issued to settle debt (in shares)", "terseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r339", "r383", "r1193", "r1206", "r1207", "r1361", "r1364", "r1365", "r1366", "r1368", "r1529", "r1530", "r1535", "r1536" ] }, "pmi_StockIssuedDuringPeriodSharesConvertibleNotes": { "xbrltype": "sharesItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "StockIssuedDuringPeriodSharesConvertibleNotes", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Common Stock issued for conversion of Convertible Notes (in shares)", "documentation": "The shares of stock issued during the period for convertible notes." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation - Unicorn (in shares)", "terseLabel": "Stock Issued During Period, Shares, Issued for Services (in shares)", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [ "r1193", "r1206", "r1207", "r1364", "r1365" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Common Stock issuance (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r866", "r949", "r979", "r1193", "r1206", "r1207", "r1361", "r1364", "r1365", "r1366", "r1368", "r1529", "r1530", "r1535", "r1536" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Stock options exercised (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)", "negatedTerseLabel": "Exercised, outstanding (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r483", "r1193", "r1206", "r1207", "r1361", "r1364", "r1365", "r1366", "r1368", "r1529", "r1530", "r1535", "r1536" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Common Stock issued to settle debt", "terseLabel": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r1193", "r1206", "r1207", "r1361", "r1364", "r1365", "r1366", "r1368", "r1529", "r1530", "r1535", "r1536" ] }, "pmi_StockIssuedDuringPeriodValueConvertibleNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "StockIssuedDuringPeriodValueConvertibleNotes", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Common Stock issued for conversion of Convertible Notes", "documentation": "The amount of stock issued during the period for convertible notes." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Common Stock issuance", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r875", "r949", "r979", "r1165", "r1193", "r1206", "r1207", "r1361", "r1364", "r1365", "r1366", "r1368", "r1529", "r1530", "r1535", "r1536" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Stock options exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r1193", "r1206", "r1207", "r1361", "r1364", "r1365", "r1366", "r1368", "r1529", "r1530", "r1535", "r1536" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Stockholders\u2019 equity (deficit)", "periodStartLabel": "Balances", "periodEndLabel": "Balances", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r45", "r908", "r925", "r950", "r951", "r1134", "r1166", "r1214", "r1281", "r1285", "r1286", "r1317", "r1510", "r1588" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 deficit:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r86", "r118", "r119", "r125", "r365", "r368", "r370", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r383", "r388", "r389", "r392", "r394", "r395", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r619", "r639", "r640", "r729", "r952", "r954", "r983" ] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-1-description-of-business-basis-of-presentation-and-managements-plan-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r1369", "r1370", "r1371" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r690", "r727" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventTable", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r690", "r727" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r690", "r727" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r690", "r727" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r726", "r728" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-changes-in-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q", "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "pmi_SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SummaryOfCommonStockReservedForFutureIssuanceTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-tables", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-tables" ], "lang": { "en-us": { "role": { "label": "Summary of Common Stock Reserved for Future Issuance [Table Text Block]", "documentation": "Summary of Common Stock Reserved for Future Issuance" } } }, "auth_ref": [] }, "pmi_SummaryOfFinanceAndOperatingRightofuseAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SummaryOfFinanceAndOperatingRightofuseAssetsTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-tables", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-tables" ], "lang": { "en-us": { "role": { "label": "Summary of Finance and Operating Right-of-Use Assets [Table Text Block]", "documentation": "Tabular disclosure of finance and operating right-of-use assets." } } }, "auth_ref": [] }, "pmi_SummaryOfFutureMinimumOperatingAndFinanceLeasePaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SummaryOfFutureMinimumOperatingAndFinanceLeasePaymentsTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-tables", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-tables" ], "lang": { "en-us": { "role": { "label": "Summary of Future Minimum Operating and Finance Lease Payments [Table Text Block]", "documentation": "Tabular disclosure of future minimum operating and finance lease payments." } } }, "auth_ref": [] }, "pmi_SummaryOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SummaryOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-tables", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "lang": { "en-us": { "role": { "label": "Summary of Property, Plant, and Equipment Estimated Useful Lives [Table Text Block]", "documentation": "Tabular disclosure of the useful lives of property, plant and equipment." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q" ], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r1191" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "pmi_SyncardiaMedicalBeijingMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "SyncardiaMedicalBeijingMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "SynCardia Medical, Beijing [Member]", "documentation": "SynCardia Medical, Beijing" } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TableTextBlock", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-tables", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-tables", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-tables", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-10q-tables", "http://picardmedical.com/20260331/role/statement-note-12-net-loss-per-share-tables", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-10q-tables", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-10q-tables", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-tables", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-tables", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-tables", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-tables", "http://picardmedical.com/20260331/role/statement-note-5-revenue-tables", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-10q-tables", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-tables", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-tables", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-tables", "http://picardmedical.com/20260331/role/statement-note-8-debt-tables", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-tables", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-tables" ], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "pmi_TahdriverEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "TahdriverEquipmentMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "http://picardmedical.com/20260331/role/statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details" ], "lang": { "en-us": { "role": { "label": "TAH-Driver Equipment [Member]", "documentation": "TAH-Driver Equipment." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TemporaryEquityAbstract", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Temporary equity:" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "calculation": { "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.0001 par value; 30,000,000 shares authorized; 0 and 18,406,857 Series A-1 issued and outstanding as of December 31, 2025 and 2024, respectively; liquidation value $0 and $25,405 as of December 31, 2025 and 2024, respectively", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r87", "r114", "r117", "r313", "r315", "r316", "r317", "r320", "r321", "r354", "r355", "r357", "r361", "r393", "r521", "r523", "r788", "r789", "r797", "r822" ] }, "pmi_TemporaryEquityGainLossOnSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "TemporaryEquityGainLossOnSettlement", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_TemporaryEquityGainLossOnSettlement", "terseLabel": "Temporary Equity, Gain (Loss) on Settlement", "documentation": "Temporary Equity, Gain (Loss) on Settlement" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityLiquidationPreference": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TemporaryEquityLiquidationPreference", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "Preferred stock, liquidation preference", "terseLabel": "Temporary Equity, Liquidation Preference", "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r788", "r789", "r797", "r1194", "r1204" ] }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": [ "r1194", "r1204", "r1529", "r1530", "r1534" ] }, "pmi_TemporaryEquityProceedsPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "TemporaryEquityProceedsPerShare", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_TemporaryEquityProceedsPerShare", "terseLabel": "Temporary Equity, Proceeds Per Share (in dollars per share)", "documentation": "Temporary Equity, Proceeds Per Share" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TemporaryEquitySharesAuthorized", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, authorized (in shares)", "terseLabel": "Temporary Equity, Shares Authorized (in shares)", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r87", "r114", "r357", "r788", "r789", "r797" ] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TemporaryEquitySharesIssued", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, issued (in shares)", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r87", "r114", "r357", "r788", "r789", "r797" ] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets-parentheticals", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-deficit-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, outstanding (in shares)", "terseLabel": "Temporary Equity, Shares Outstanding (in shares)", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r87", "r114", "r357", "r788", "r789", "r797" ] }, "pmi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "terseLabel": "Temporary Equity, Stock Issued During Period, Shares, New Issues (in shares)", "documentation": "Shares of new stock classified as temporary equity issued during the period." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "terseLabel": "Temporary Equity, Stock Issued During Period, Value, New Issues", "documentation": "Value of new stock classified as temporary equity issued during the period." } } }, "auth_ref": [ "r1194", "r1205", "r1356", "r1357", "r1358", "r1359", "r1529", "r1530", "r1534" ] }, "pmi_TexasComptrollerOfPublicAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "TexasComptrollerOfPublicAccountsMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details" ], "lang": { "en-us": { "role": { "label": "Texas Comptroller of Public Accounts [Member]", "documentation": "Related to the Texas Comptroller of Public Accounts." } } }, "auth_ref": [] }, "pmi_The2021EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "The2021EquityIncentivePlanMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-10-share-based-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2021 Equity Incentive Plan [Member]", "documentation": "The 2021 Equity Incentive Plan" } } }, "auth_ref": [] }, "pmi_The2023ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "The2023ConvertibleNotesMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details" ], "lang": { "en-us": { "role": { "label": "The 2023 Convertible Notes [Member]", "documentation": "The 2023 Convertible Notes" } } }, "auth_ref": [] }, "pmi_The2024ConvertibleNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "The2024ConvertibleNoteMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details" ], "lang": { "en-us": { "role": { "label": "The 2024 Convertible Note [Member]", "documentation": "The 2024 Convertible Note" } } }, "auth_ref": [] }, "pmi_The2025SeniorSecuredNoteHoldersMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "The2025SeniorSecuredNoteHoldersMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "The 2025 Senior Secured Note Holders [Member]", "documentation": "Represents noteholders of the 2025 Senior Secured Note." } } }, "auth_ref": [] }, "pmi_The2025SeniorSecuredNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "The2025SeniorSecuredNoteMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-summary-of-convertible-note-balances-details" ], "lang": { "en-us": { "role": { "label": "The 2025 Senior Secured Note [Member]", "documentation": "Represents the 2025 Senior Secured Note." } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r1313", "r1314", "r1316" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TradeNamesMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-details-textual", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-10q-details", "http://picardmedical.com/20260331/role/statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-details" ], "lang": { "en-us": { "role": { "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r1085", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1328", "r1331", "r1332", "r1333" ] }, "pmi_TusconAzLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "TusconAzLeaseMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Tuscon, AZ Lease [Member]", "documentation": "Tuscon, AZ Lease" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TypeOfArrangementAxis", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r589" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2026", "localname": "US", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes", "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q", "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-10q-details", "http://picardmedical.com/20260331/role/statement-note-5-revenue-disaggregation-of-revenue-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-10q-details", "http://picardmedical.com/20260331/role/statement-note-6-concentrations-summary-of-longlived-assets-by-area-details" ], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_UnbilledContractsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "UnbilledContractsReceivable", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-5-revenue-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-5-revenue-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnbilledContractsReceivable", "terseLabel": "Unbilled Contracts Receivable", "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet." } } }, "auth_ref": [ "r749" ] }, "pmi_UnderwriterCommissionsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "UnderwriterCommissionsAndExpenses", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_UnderwriterCommissionsAndExpenses", "terseLabel": "Underwriter Commissions and Expenses", "documentation": "Underwriter Commissions and Expenses" } } }, "auth_ref": [] }, "pmi_UnderwriterCommissionsIssuerCounselExpensesInvestorRelationsPromotionsAndOtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "UnderwriterCommissionsIssuerCounselExpensesInvestorRelationsPromotionsAndOtherExpenses", "crdr": "debit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_UnderwriterCommissionsIssuerCounselExpensesInvestorRelationsPromotionsAndOtherExpenses", "terseLabel": "Underwriter Commissions, Issuer Counsel, Expenses, Investor Relations, Promotions, and Other Expenses", "documentation": "The amount of underwriter commissions, issuer counsel, expenses, investor relations, promotions, and other expenses." } } }, "auth_ref": [] }, "pmi_UnicornAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "UnicornAgreementMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit", "http://picardmedical.com/20260331/role/statement-note-9-temporary-equity-and-stockholders-equity-deficit-details-textual" ], "lang": { "en-us": { "role": { "label": "Unicorn Agreement [Member]", "documentation": "The Unicorn Agreement" } } }, "auth_ref": [] }, "pmi_UnitsIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "UnitsIssuedPricePerShare", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual" ], "lang": { "en-us": { "role": { "label": "pmi_UnitsIssuedPricePerShare", "terseLabel": "Units Issued, Price Per Share (in dollars per share)", "documentation": "The price per share of units issued during the period." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r546", "r1077" ] }, "us-gaap_UnsecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "UnsecuredDebt", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_UnsecuredDebt", "terseLabel": "Unsecured Debt", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": [ "r1197", "r1202", "r1540" ] }, "pmi_UnsecuredDebtConvertedToCommonSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "UnsecuredDebtConvertedToCommonSharesMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-8-debt", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "Unsecured Debt Converted to Common Shares [Member]", "documentation": "Represents information pertaining to the unsecured debt converted into common shares." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "UseOfEstimates", "presentation": [ "http://picardmedical.com/20260331/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r62", "r63", "r214", "r218", "r219", "r220", "r807", "r809", "r1031" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-11-income-taxes-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r550" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 0.0 }, "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-10q-details": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-10q-details", "http://picardmedical.com/20260331/role/statement-note-7-commitments-and-contingencies-summary-of-lease-costs-details" ], "lang": { "en-us": { "role": { "label": "us-gaap_VariableLeaseCost", "terseLabel": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r702", "r1125" ] }, "pmi_VersaCapitalManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "VersaCapitalManagementMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Versa Capital Management [Member]", "documentation": "Versa Capital Management" } } }, "auth_ref": [] }, "pmi_VersaNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "VersaNoteMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions", "http://picardmedical.com/20260331/role/statement-note-14-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Versa Note [Member]", "documentation": "Versa Note" } } }, "auth_ref": [] }, "pmi_WarrantLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "WarrantLiabilityMember", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-balance-sheets", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "http://picardmedical.com/20260331/role/statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-balance-sheets" ], "lang": { "en-us": { "role": { "label": "Warrant Liability [Member]", "documentation": "Represents warrant liability." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://picardmedical.com/20260331/role/statement-note-15-subsequent-events-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-10q-details-textual", "http://picardmedical.com/20260331/role/statement-note-8-debt-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term (Year)", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1490", "r1491", "r1492" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://picardmedical.com/20260331/role/statement-unaudited-condensed-consolidated-statements-of-operations-and-comprehensive-loss" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding\u2014basic and diluted (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r193", "r201" ] }, "pmi_WriteoffOfRelatedPartyReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "WriteoffOfRelatedPartyReceivable", "crdr": "credit", "presentation": [ "http://picardmedical.com/20260331/role/statement-consolidated-statements-of-cash-flows" ], "lang": { "en-us": { "role": { "label": "Write-off of related party receivable", "documentation": "Amount of write-off of related party receivable." } } }, "auth_ref": [] }, "pmi_statement-statement-note-10-share-based-compensation-10q-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-10-share-based-compensation-10q-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Share Based Compensation -10-Q" } } }, "auth_ref": [] }, "pmi_statement-statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-10q-details", "lang": { "en-us": { "role": { "label": "Note 10 - Share Based Compensation - Allocation of Stock-based Compensation Expense -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-10-share-based-compensation-allocation-of-stockbased-compensation-expense-details", "lang": { "en-us": { "role": { "label": "Note 10 - Share Based Compensation - Allocation of Stock-based Compensation Expense (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-10-share-based-compensation-summary-of-stock-option-transactions-10q-details", "lang": { "en-us": { "role": { "label": "Note 10 - Share Based Compensation - Summary of Stock Option Transactions -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-10-share-based-compensation-summary-of-stock-option-transactions-details", "lang": { "en-us": { "role": { "label": "Note 10 - Share Based Compensation - Summary of Stock Option Transactions (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-10-share-based-compensation-summary-of-valuation-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-10-share-based-compensation-summary-of-valuation-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 10 - Share Based Compensation - Summary of Valuation Assumptions (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-10-share-based-compensation-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-10-share-based-compensation-tables", "lang": { "en-us": { "role": { "label": "Note 10 - Share Based Compensation" } } }, "auth_ref": [] }, "pmi_statement-statement-note-10-share-based-compensation-valuation-assumptions-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-10-share-based-compensation-valuation-assumptions-10q-details", "lang": { "en-us": { "role": { "label": "Note 10 - Share Based Compensation - Valuation Assumptions -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-11-income-taxes-components-and-income-loss-before-income-taxes-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-11-income-taxes-components-and-income-loss-before-income-taxes-details", "lang": { "en-us": { "role": { "label": "Note 11 - Income Taxes - Components and Income (Loss) Before Income Taxes (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-11-income-taxes-components-of-deferred-tax-assets-and-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 11 - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-11-income-taxes-income-taxes-paid-by-jurisdiction-details", "lang": { "en-us": { "role": { "label": "Note 11 - Income Taxes - Income Taxes Paid By Jurisdiction (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-11-income-taxes-reconciliation-of-benefits-for-income-taxes-details", "lang": { "en-us": { "role": { "label": "Note 11 - Income Taxes - Reconciliation of Benefits for Income Taxes (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-11-income-taxes-schedule-of-components-for-income-taxes-details", "lang": { "en-us": { "role": { "label": "Note 11 - Income Taxes - Schedule of Components for Income Taxes (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-11-income-taxes-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-11-income-taxes-tables", "lang": { "en-us": { "role": { "label": "Note 11 - Income Taxes" } } }, "auth_ref": [] }, "pmi_statement-statement-note-12-net-loss-per-share-10q-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-12-net-loss-per-share-10q-tables", "lang": { "en-us": { "role": { "label": "Note 12 - Net Loss Per Share -10-Q" } } }, "auth_ref": [] }, "pmi_statement-statement-note-12-net-loss-per-share-antidilutive-securities-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-12-net-loss-per-share-antidilutive-securities-10q-details", "lang": { "en-us": { "role": { "label": "Note 12 - Net Loss Per Share - Antidilutive Securities -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-12-net-loss-per-share-antidilutive-securities-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-12-net-loss-per-share-antidilutive-securities-details", "lang": { "en-us": { "role": { "label": "Note 12 - Net Loss Per Share - Antidilutive Securities (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-12-net-loss-per-share-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-12-net-loss-per-share-tables", "lang": { "en-us": { "role": { "label": "Note 12 - Net Loss Per Share" } } }, "auth_ref": [] }, "pmi_statement-statement-note-2-summary-of-significant-accounting-policies-10q-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-10q-tables", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies -10-Q" } } }, "auth_ref": [] }, "pmi_statement-statement-note-2-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "pmi_statement-statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-10q-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Useful Lives of Property and Equipment -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-useful-lives-of-property-and-equipment-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Useful Lives of Property and Equipment (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-3-fair-value-of-financial-instruments-10q-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-3-fair-value-of-financial-instruments-10q-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value of Financial Instruments -10-Q" } } }, "auth_ref": [] }, "pmi_statement-statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-10q-details", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value of Financial Instruments - Fair Values of Derivative Liabilities -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-3-fair-value-of-financial-instruments-fair-values-of-derivative-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value of Financial Instruments - Fair Values of Derivative Liabilities (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value of Financial Instruments - Summary of Fair Value Measurements -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details-parentheticals": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-10q-details-parentheticals", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value of Financial Instruments - Summary of Fair Value Measurements -10-Q (Details) (Parentheticals)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value of Financial Instruments - Summary of Fair Value Measurements (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details-parentheticals": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-3-fair-value-of-financial-instruments-summary-of-fair-value-measurements-details-parentheticals", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value of Financial Instruments - Summary of Fair Value Measurements (Details) (Parentheticals)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-3-fair-value-of-financial-instruments-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-3-fair-value-of-financial-instruments-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value of Financial Instruments" } } }, "auth_ref": [] }, "pmi_statement-statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-3-fair-value-of-financial-instruments-valuation-measurements-10q-details", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value of Financial Instruments - Valuation Measurements -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-3-fair-value-of-financial-instruments-valuation-measurements-details", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value of Financial Instruments - Valuation Measurements (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-4-certain-balance-sheet-components-10q-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-4-certain-balance-sheet-components-10q-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Certain Balance Sheet Components -10-Q" } } }, "auth_ref": [] }, "pmi_statement-statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-10q-details", "lang": { "en-us": { "role": { "label": "Note 4 - Certain Balance Sheet Components - Estimated Future Amortization Expenses -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-4-certain-balance-sheet-components-estimated-future-amortization-expenses-details", "lang": { "en-us": { "role": { "label": "Note 4 - Certain Balance Sheet Components - Estimated Future Amortization Expenses (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-10q-details", "lang": { "en-us": { "role": { "label": "Note 4 - Certain Balance Sheet Components - Summary of Intangible Assets -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-4-certain-balance-sheet-components-summary-of-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Note 4 - Certain Balance Sheet Components - Summary of Intangible Assets (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-4-certain-balance-sheet-components-summary-of-inventory-10q-details", "lang": { "en-us": { "role": { "label": "Note 4 - Certain Balance Sheet Components - Summary of Inventory -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-4-certain-balance-sheet-components-summary-of-inventory-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-4-certain-balance-sheet-components-summary-of-inventory-details", "lang": { "en-us": { "role": { "label": "Note 4 - Certain Balance Sheet Components - Summary of Inventory (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-10q-details", "lang": { "en-us": { "role": { "label": "Note 4 - Certain Balance Sheet Components - Summary of Other Accrued Liabilities -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-4-certain-balance-sheet-components-summary-of-other-accrued-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 4 - Certain Balance Sheet Components - Summary of Other Accrued Liabilities (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-10q-details", "lang": { "en-us": { "role": { "label": "Note 4 - Certain Balance Sheet Components - Summary of Property and Equipment -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-4-certain-balance-sheet-components-summary-of-property-and-equipment-details", "lang": { "en-us": { "role": { "label": "Note 4 - Certain Balance Sheet Components - Summary of Property and Equipment (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-4-certain-balance-sheet-components-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-4-certain-balance-sheet-components-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Certain Balance Sheet Components" } } }, "auth_ref": [] }, "pmi_statement-statement-note-5-revenue-10q-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-5-revenue-10q-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Revenue -10-Q" } } }, "auth_ref": [] }, "pmi_statement-statement-note-5-revenue-disaggregation-of-revenue-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-5-revenue-disaggregation-of-revenue-10q-details", "lang": { "en-us": { "role": { "label": "Note 5 - Revenue - Disaggregation of Revenue -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-5-revenue-disaggregation-of-revenue-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-5-revenue-disaggregation-of-revenue-details", "lang": { "en-us": { "role": { "label": "Note 5 - Revenue - Disaggregation of Revenue (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-5-revenue-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-5-revenue-tables", "lang": { "en-us": { "role": { "label": "Note 5 - Revenue" } } }, "auth_ref": [] }, "pmi_statement-statement-note-6-concentrations-10q-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-6-concentrations-10q-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Concentrations -10-Q" } } }, "auth_ref": [] }, "pmi_statement-statement-note-6-concentrations-summary-of-concentration-risks-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-6-concentrations-summary-of-concentration-risks-10q-details", "lang": { "en-us": { "role": { "label": "Note 6 - Concentrations - Summary of Concentration Risks -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-6-concentrations-summary-of-concentration-risks-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-6-concentrations-summary-of-concentration-risks-details", "lang": { "en-us": { "role": { "label": "Note 6 - Concentrations - Summary of Concentration Risks (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-6-concentrations-summary-of-longlived-assets-by-area-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-6-concentrations-summary-of-longlived-assets-by-area-10q-details", "lang": { "en-us": { "role": { "label": "Note 6 - Concentrations - Summary of Long-lived Assets by Area -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-6-concentrations-summary-of-longlived-assets-by-area-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-6-concentrations-summary-of-longlived-assets-by-area-details", "lang": { "en-us": { "role": { "label": "Note 6 - Concentrations - Summary of Long-lived Assets by Area (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-6-concentrations-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-6-concentrations-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Concentrations" } } }, "auth_ref": [] }, "pmi_statement-statement-note-7-commitments-and-contingencies-10q-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-7-commitments-and-contingencies-10q-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Commitments and Contingencies -10-Q" } } }, "auth_ref": [] }, "pmi_statement-statement-note-7-commitments-and-contingencies-summary-of-lease-costs-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-7-commitments-and-contingencies-summary-of-lease-costs-10q-details", "lang": { "en-us": { "role": { "label": "Note 7 - Commitments and Contingencies - Summary of Lease Costs -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-7-commitments-and-contingencies-summary-of-lease-costs-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-7-commitments-and-contingencies-summary-of-lease-costs-details", "lang": { "en-us": { "role": { "label": "Note 7 - Commitments and Contingencies - Summary of Lease Costs (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-10q-details", "lang": { "en-us": { "role": { "label": "Note 7 - Commitments and Contingencies - Summary of Lease Payment Obligations -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-7-commitments-and-contingencies-summary-of-lease-payment-obligations-details", "lang": { "en-us": { "role": { "label": "Note 7 - Commitments and Contingencies - Summary of Lease Payment Obligations (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-10q-details", "lang": { "en-us": { "role": { "label": "Note 7 - Commitments and Contingencies - Summary of Right-of-Use Assets -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-7-commitments-and-contingencies-summary-of-rightofuse-assets-details", "lang": { "en-us": { "role": { "label": "Note 7 - Commitments and Contingencies - Summary of Right-of-Use Assets (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-7-commitments-and-contingencies-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-7-commitments-and-contingencies-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Commitments and Contingencies" } } }, "auth_ref": [] }, "pmi_statement-statement-note-8-debt-summary-of-convertible-note-balances-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-8-debt-summary-of-convertible-note-balances-details", "lang": { "en-us": { "role": { "label": "Note 8 - Debt - Summary of Convertible Note Balances (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-8-debt-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-8-debt-tables", "lang": { "en-us": { "role": { "label": "Note 8 - Debt" } } }, "auth_ref": [] }, "pmi_statement-statement-note-9-temporary-equity-and-stockholders-deficit-10q-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-9-temporary-equity-and-stockholders-deficit-10q-tables", "lang": { "en-us": { "role": { "label": "Note 9 - Temporary Equity and Stockholders' Deficit -10-Q" } } }, "auth_ref": [] }, "pmi_statement-statement-note-9-temporary-equity-and-stockholders-deficit-reserved-common-stock-10q-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-9-temporary-equity-and-stockholders-deficit-reserved-common-stock-10q-details", "lang": { "en-us": { "role": { "label": "Note 9 - Temporary Equity and Stockholders' Deficit - Reserved Common Stock -10-Q (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-9-temporary-equity-and-stockholders-equity-deficit-reserved-common-stock-details": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-9-temporary-equity-and-stockholders-equity-deficit-reserved-common-stock-details", "lang": { "en-us": { "role": { "label": "Note 9 - Temporary Equity and Stockholders' Equity (Deficit) - Reserved Common Stock (Details)" } } }, "auth_ref": [] }, "pmi_statement-statement-note-9-temporary-equity-and-stockholders-equity-deficit-tables": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-note-9-temporary-equity-and-stockholders-equity-deficit-tables", "lang": { "en-us": { "role": { "label": "Note 9 - Temporary Equity and Stockholders' Equity (Deficit)" } } }, "auth_ref": [] }, "pmi_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://picardmedical.com/20260331", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } }, "ex_965312.htm": { "dts": { "inline": { "local": [ "ex_965312.htm" ] }, "schema": { "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.sec.gov/dei/2026/dei-2026.xsd", "https://xbrl.sec.gov/ffd/2026/ffd-2026.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 0, "hidden": { "total": 8, "http://xbrl.sec.gov/ffd/2026": 6, "http://xbrl.sec.gov/dei/2026": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 1, "elementCount": 107, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/ffd/2026": 32, "http://xbrl.sec.gov/dei/2026": 3 }, "report": { "R137": { "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable", "longName": "995210 - Document - Submission", "shortName": "Submission", "isDefault": "true", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Cover", "order": "137", "firstAnchor": null, "uniqueAnchor": null }, "R138": { "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable", "longName": "995211 - Document - Offerings", "shortName": "Offerings", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Cover", "order": "138", "firstAnchor": { "contextRef": "offrl_1", "name": "ffd:PrevslyPdFlg", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ex_965312.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "offrl_1", "name": "ffd:PrevslyPdFlg", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ex_965312.htm", "first": true, "unique": true } }, "R139": { "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable", "longName": "995215 - Document - Fees Summary", "shortName": "Fees Summary", "isDefault": "false", "groupType": "Fee_Exhibit", "subGroupType": "", "menuCat": "Cover", "order": "139", "firstAnchor": { "contextRef": "rc", "name": "ffd:TtlOfferingAmt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ex_965312.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "rc", "name": "ffd:TtlOfferingAmt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ex_965312.htm", "first": true, "unique": true } } }, "tag": { "ffd_AggtRedRpPricFsclYr": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "AggtRedRpPricFsclYr", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year", "terseLabel": "Aggregate Redeemed or Repurchased, FY" } } }, "auth_ref": [ "r1168" ] }, "ffd_AggtRedRpPricPrrFsclYr": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "AggtRedRpPricPrrFsclYr", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year", "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY" } } }, "auth_ref": [ "r1168" ] }, "ffd_AggtSalesPricFsclYr": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "AggtSalesPricFsclYr", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Aggregate Sales Price, Fiscal Year", "terseLabel": "Aggregate Sales Price" } } }, "auth_ref": [ "r1168" ] }, "ffd_AmtRedCdts": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "AmtRedCdts", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Amount of Redemption Credits", "terseLabel": "Redemption Credits" } } }, "auth_ref": [ "r1168" ] }, "ffd_AmtSctiesRcvd": { "xbrltype": "nonNegativeDecimal2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "AmtSctiesRcvd", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Amount of Securities Received", "terseLabel": "Amount of Securities Received", "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)" } } }, "auth_ref": [ "r1173" ] }, "ffd_AmtSctiesRegd": { "xbrltype": "nonNegativeDecimal2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "AmtSctiesRegd", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Amount of Securities Registered", "terseLabel": "Amount Registered", "documentation": "The amount of securities being registered." } } }, "auth_ref": [ "r1168" ] }, "ffd_CeasedOprsDt": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CeasedOprsDt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Ceased Operations Date", "terseLabel": "Ceased Operations Date" } } }, "auth_ref": [] }, "ffd_CfwdFormTp": { "xbrltype": "formTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CfwdFormTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Carry Forward Form Type", "terseLabel": "Carry Forward Form Type", "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)." } } }, "auth_ref": [ "r1169" ] }, "ffd_CfwdPrevslyPdFee": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CfwdPrevslyPdFee", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Carry Forward Previously Paid Fee", "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward", "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)." } } }, "auth_ref": [ "r1169" ] }, "ffd_CfwdPrrFctvDt": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CfwdPrrFctvDt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Carry Forward Prior Effective Date", "terseLabel": "Carry Forward Initial Effective Date", "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)." } } }, "auth_ref": [ "r1169" ] }, "ffd_CfwdPrrFileNb": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CfwdPrrFileNb", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Carry Forward File Number", "terseLabel": "Carry Forward File Number", "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used." } } }, "auth_ref": [ "r1169" ] }, "ffd_CmbndPrspctsItemAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CmbndPrspctsItemAxis", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Combined Prospectus Item [Axis]", "terseLabel": "Combined Prospectus", "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission." } } }, "auth_ref": [ "r1168" ] }, "ffd_CmbndPrspctsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CmbndPrspctsLineItems", "lang": { "en-us": { "role": { "label": "Combined Prospectus [Line Items]", "terseLabel": "Combined Prospectus:" } } }, "auth_ref": [ "r1168" ] }, "ffd_CmbndPrspctsTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CmbndPrspctsTable", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Combined Prospectus [Table]", "terseLabel": "Combined Prospectus Table" } } }, "auth_ref": [ "r1168" ] }, "ffd_CombinedProspectusTableNa": { "xbrltype": "naItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CombinedProspectusTableNa", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Combined Prospectus Table [N/A]", "terseLabel": "Combined Prospectus Table N/A" } } }, "auth_ref": [] }, "ffd_CshPdByRegistrantInTx": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CshPdByRegistrantInTx", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Cash Paid by Registrant in Transaction", "terseLabel": "Cash Consideration Paid", "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)." } } }, "auth_ref": [ "r1179" ] }, "ffd_CshRcvdByRegistrantInTx": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "CshRcvdByRegistrantInTx", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Cash Received by Registrant in Transaction", "terseLabel": "Cash Consideration Received", "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)." } } }, "auth_ref": [ "r1179" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCentralIndexKey", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1167" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityRegistrantName", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1167" ] }, "ffd_FeeAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeeAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable", "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Fee Amount", "terseLabel": "Amount of Registration Fee", "documentation": "Total amount of registration fee (amount due after offsets)." } } }, "auth_ref": [ "r1168" ] }, "ffd_FeeExhibitTp": { "xbrltype": "feeExhibitTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeeExhibitTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Fee Exhibit Type", "terseLabel": "Fee Exhibit Type" } } }, "auth_ref": [] }, "ffd_FeeIntrstAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeeIntrstAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Fee Interest Amount", "terseLabel": "Interest Amount" } } }, "auth_ref": [ "r1168" ] }, "ffd_FeeNote": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeeNote", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Fee Note", "terseLabel": "Fee Note" } } }, "auth_ref": [ "r1168" ] }, "ffd_FeeNoteMaxAggtOfferingPric": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeeNoteMaxAggtOfferingPric", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Fee Note Maximum Aggregate Offering Price", "terseLabel": "Fee Note MAOP" } } }, "auth_ref": [ "r1168" ] }, "ffd_FeeRate": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeeRate", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable", "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Fee Rate", "terseLabel": "Fee Rate", "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission." } } }, "auth_ref": [ "r1168" ] }, "ffd_FeesOthrRuleFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeesOthrRuleFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Fees, Other Rule [Flag]", "terseLabel": "Other Rule", "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due." } } }, "auth_ref": [ "r1168" ] }, "ffd_FeesSummaryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FeesSummaryLineItems", "lang": { "en-us": { "role": { "label": "Fees Summary [Line Items]", "terseLabel": "Fees Summary:" } } }, "auth_ref": [ "r1168" ] }, "ffd_FnlPrspctsFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FnlPrspctsFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Final Prospectus [Flag]", "terseLabel": "Final Prospectus" } } }, "auth_ref": [ "r1168" ] }, "ffd_FormTp": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "FormTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Form Type", "terseLabel": "Form Type" } } }, "auth_ref": [] }, "ffd_GnlInstrIIhiFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "GnlInstrIIhiFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "General Instruction II.H,I [Flag]", "terseLabel": "General Instruction II.H,I" } } }, "auth_ref": [] }, "ffd_IssrBizAdrCity": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "IssrBizAdrCity", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Issuer Business Address, City", "terseLabel": "City" } } }, "auth_ref": [] }, "ffd_IssrBizAdrStatOrCtryCd": { "xbrltype": "stateOrCountryCodeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "IssrBizAdrStatOrCtryCd", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Issuer Business Address, State or Country Code", "terseLabel": "State or Country Code" } } }, "auth_ref": [] }, "ffd_IssrBizAdrStrt1": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "IssrBizAdrStrt1", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Issuer Business Address, Street 1", "terseLabel": "Street 1" } } }, "auth_ref": [] }, "ffd_IssrBizAdrStrt2": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "IssrBizAdrStrt2", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Issuer Business Address, Street 2", "terseLabel": "Street 2" } } }, "auth_ref": [] }, "ffd_IssrBizAdrZipCd": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "IssrBizAdrZipCd", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Issuer Business Address, Zip Code", "terseLabel": "Zip Code" } } }, "auth_ref": [] }, "ffd_IssrNm": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "IssrNm", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Issuer Name", "terseLabel": "Issuer Name" } } }, "auth_ref": [] }, "ffd_MaxAggtOfferingPric": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "MaxAggtOfferingPric", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Maximum Aggregate Offering Price", "terseLabel": "Maximum Aggregate Offering Price", "documentation": "The maximum aggregate offering price for the offering that is being registered." } } }, "auth_ref": [ "r1168" ] }, "ffd_MaxOfferingPricPerScty": { "xbrltype": "nonNegativeDecimal4lItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "MaxOfferingPricPerScty", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Maximum Offering Price per Security", "terseLabel": "Proposed Maximum Offering Price per Unit", "documentation": "The maximum offering price per share/unit being registered." } } }, "auth_ref": [ "r1168" ] }, "ffd_NetFeeAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "NetFeeAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Net Fee Amount", "terseLabel": "Net Fee" } } }, "auth_ref": [ "r1168" ] }, "ffd_NetSalesAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "NetSalesAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Net Sales Amount", "terseLabel": "Net Sales" } } }, "auth_ref": [ "r1168" ] }, "ffd_NrrtvDsclsr": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "NrrtvDsclsr", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Narrative Disclosure", "terseLabel": "Narrative Disclosure" } } }, "auth_ref": [ "r1168" ] }, "ffd_NrrtvMaxAggtAmt": { "xbrltype": "nonNegativeDecimal2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "NrrtvMaxAggtAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Narrative Disclosure, Maximum Aggregate Offering Amount", "terseLabel": "Narrative - Max Aggregate Offering Amount" } } }, "auth_ref": [ "r1168" ] }, "ffd_NrrtvMaxAggtOfferingPric": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "NrrtvMaxAggtOfferingPric", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Narrative Disclosure, Maximum Aggregate Offering Price", "terseLabel": "Narrative - Max Aggregate Offering Price" } } }, "auth_ref": [ "r1168" ] }, "ffd_OfferingAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OfferingAxis", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Offering [Axis]", "terseLabel": "Offering", "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission." } } }, "auth_ref": [] }, "ffd_OfferingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OfferingLineItems", "lang": { "en-us": { "role": { "label": "Offering [Line Items]", "terseLabel": "Offering:" } } }, "auth_ref": [] }, "ffd_OfferingNote": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OfferingNote", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Offering Note", "terseLabel": "Offering Note" } } }, "auth_ref": [ "r1168" ] }, "ffd_OfferingSctyTitl": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OfferingSctyTitl", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable", "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Offering Security Title", "terseLabel": "Security Class Title", "documentation": "The title of the class of securities being registered (for each class being registered)." } } }, "auth_ref": [ "r1168" ] }, "ffd_OfferingSctyTp": { "xbrltype": "securityTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OfferingSctyTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Offering Security Type", "terseLabel": "Security Type", "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\"" } } }, "auth_ref": [ "r1168" ] }, "ffd_OfferingTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OfferingTable", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Offering [Table]", "terseLabel": "Offering:" } } }, "auth_ref": [] }, "ffd_OfferingTableNa": { "xbrltype": "naItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OfferingTableNa", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Offering Table [N/A]", "terseLabel": "Offering Table N/A" } } }, "auth_ref": [] }, "ffd_OffsetAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetAxis", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset [Axis]", "terseLabel": "Offset", "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission." } } }, "auth_ref": [ "r1168" ] }, "ffd_OffsetClmInitlFilgDt": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetClmInitlFilgDt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Claim Initial Filing Date", "terseLabel": "Initial Filing Date", "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ." } } }, "auth_ref": [ "r1172", "r1175" ] }, "ffd_OffsetClmdAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetClmdAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Claimed Amount", "terseLabel": "Fee Offset Claimed", "documentation": "The amount of offsetting fees being claimed." } } }, "auth_ref": [ "r1172", "r1175" ] }, "ffd_OffsetClmdInd": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetClmdInd", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Claimed Indicator", "terseLabel": "Offset Claimed" } } }, "auth_ref": [ "r1168" ] }, "ffd_OffsetExpltnForClmdAmt": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetExpltnForClmdAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Explanation for Claimed Amount", "terseLabel": "Explanation for Claimed Amount" } } }, "auth_ref": [ "r1168" ] }, "ffd_OffsetLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetLineItems", "lang": { "en-us": { "role": { "terseLabel": "Offset:", "label": "Offset [Line Items]" } } }, "auth_ref": [ "r1168" ] }, "ffd_OffsetNote": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetNote", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Note", "terseLabel": "Offset Note" } } }, "auth_ref": [ "r1168" ] }, "ffd_OffsetPrrFeeAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrFeeAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior Fee Amount", "terseLabel": "Fee Paid with Fee Offset Source", "documentation": "The fee previously paid from which an offset is being derived." } } }, "auth_ref": [ "r1172", "r1175" ] }, "ffd_OffsetPrrFileNb": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrFileNb", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior File Number", "terseLabel": "File Number", "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used." } } }, "auth_ref": [ "r1172", "r1175" ] }, "ffd_OffsetPrrFilerNm": { "xbrltype": "filerNameItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrFilerNm", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior Filer Name", "terseLabel": "Registrant or Filer Name", "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid." } } }, "auth_ref": [ "r1172", "r1175" ] }, "ffd_OffsetPrrFormTp": { "xbrltype": "formTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrFormTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior Form Type", "terseLabel": "Form or Filing Type", "documentation": "The Form Type of the offset filing." } } }, "auth_ref": [ "r1172", "r1175" ] }, "ffd_OffsetPrrNbOfUnsoldScties": { "xbrltype": "nonNegativeDecimal8ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrNbOfUnsoldScties", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior Unsold Number of Securities", "terseLabel": "Unsold Securities Associated with Fee Offset Claimed", "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset." } } }, "auth_ref": [ "r1172", "r1175" ] }, "ffd_OffsetPrrSctyTitl": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrSctyTitl", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior Security Title", "terseLabel": "Security Title Associated with Fee Offset Claimed", "documentation": "The title of the class of securities from which offset fees were derived." } } }, "auth_ref": [ "r1172", "r1175" ] }, "ffd_OffsetPrrSctyTp": { "xbrltype": "securityTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrSctyTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior Security Type", "terseLabel": "Security Type Associated with Fee Offset Claimed", "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\"" } } }, "auth_ref": [ "r1172", "r1175" ] }, "ffd_OffsetPrrUnsoldOfferingAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetPrrUnsoldOfferingAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Prior Unsold Offering Amount", "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed", "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset." } } }, "auth_ref": [ "r1172", "r1175" ] }, "ffd_OffsetSrcFilgDt": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetSrcFilgDt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Offset Source Filing Date", "terseLabel": "Filing Date", "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset." } } }, "auth_ref": [ "r1172", "r1175" ] }, "ffd_OffsetTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetTable", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Offset Payment:", "label": "Offset [Table]" } } }, "auth_ref": [ "r1168" ] }, "ffd_OffsetTableNa": { "xbrltype": "naItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "OffsetTableNa", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Offset Table [N/A]", "terseLabel": "Offset Table N/A" } } }, "auth_ref": [] }, "ffd_PrevslyPdFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "PrevslyPdFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable", "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Fee Previously Paid [Flag]", "terseLabel": "Fee Previously Paid" } } }, "auth_ref": [] }, "ffd_RegnFileNb": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "RegnFileNb", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Registration File Number", "terseLabel": "Registration File Number" } } }, "auth_ref": [] }, "ffd_RptgFsclYrEndDt": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "RptgFsclYrEndDt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Reporting Fiscal Year End Date", "terseLabel": "Reporting FY End Date" } } }, "auth_ref": [] }, "ffd_Rule011Flg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule011Flg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 0-11 [Flag]", "terseLabel": "Rule 0-11" } } }, "auth_ref": [] }, "ffd_Rule011a2OffsetFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule011a2OffsetFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 0-11(a)(2) Offset", "label": "Rule 0-11(a)(2) Offset [Flag]" } } }, "auth_ref": [] }, "ffd_Rule415a6Flg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule415a6Flg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 415(a)(6) [Flag]", "terseLabel": "Rule 415(a)(6)", "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward." } } }, "auth_ref": [ "r1169" ] }, "ffd_Rule429AggtOfferingAmt": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429AggtOfferingAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Aggregate Offering Amount", "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered", "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement." } } }, "auth_ref": [ "r1170" ] }, "ffd_Rule429CmbndPrspctsFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429CmbndPrspctsFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Combined Prospectus [Flag]", "terseLabel": "Rule 429", "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429." } } }, "auth_ref": [ "r1170" ] }, "ffd_Rule429EarlierFileNb": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429EarlierFileNb", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Earlier File Number", "terseLabel": "File Number", "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429." } } }, "auth_ref": [ "r1170" ] }, "ffd_Rule429EarlierFormTp": { "xbrltype": "formTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429EarlierFormTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Earlier Form Type", "terseLabel": "Form Type", "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)." } } }, "auth_ref": [ "r1170" ] }, "ffd_Rule429InitlFctvDt": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429InitlFctvDt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Initial Effective Date", "terseLabel": "Initial Effective Date", "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429." } } }, "auth_ref": [ "r1170" ] }, "ffd_Rule429NbOfUnsoldScties": { "xbrltype": "nonNegativeDecimal2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429NbOfUnsoldScties", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Number Of Unsold Securities", "terseLabel": "Amount of Securities Previously Registered", "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429." } } }, "auth_ref": [ "r1170" ] }, "ffd_Rule429PrspctsNote": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429PrspctsNote", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Prospectus Note", "terseLabel": "Combined Prospectus Note" } } }, "auth_ref": [ "r1168" ] }, "ffd_Rule429SctyTitl": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429SctyTitl", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Security Title", "terseLabel": "Security Class Title" } } }, "auth_ref": [ "r1168" ] }, "ffd_Rule429SctyTp": { "xbrltype": "securityTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule429SctyTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable" ], "lang": { "en-us": { "role": { "label": "Rule 429 Security Type", "terseLabel": "Security Type" } } }, "auth_ref": [ "r1168" ] }, "ffd_Rule457aFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457aFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(a) [Flag]", "terseLabel": "Rule 457(a)", "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due." } } }, "auth_ref": [ "r1171" ] }, "ffd_Rule457bOffsetFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457bOffsetFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(b) Offset [Flag]", "terseLabel": "Rule 457(b) Offset", "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)." } } }, "auth_ref": [ "r1172" ] }, "ffd_Rule457fFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457fFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(f) [Flag]", "terseLabel": "Rule 457(f)", "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due." } } }, "auth_ref": [ "r1173" ] }, "ffd_Rule457oFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457oFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(o) [Flag]", "terseLabel": "Rule 457(o)", "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due." } } }, "auth_ref": [ "r1174" ] }, "ffd_Rule457pOffsetFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457pOffsetFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(p) Offset [Flag]", "terseLabel": "Rule 457(p) Offset", "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)." } } }, "auth_ref": [ "r1175" ] }, "ffd_Rule457rFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457rFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(r) [Flag]", "terseLabel": "Rule 457(r)" } } }, "auth_ref": [ "r1176" ] }, "ffd_Rule457sFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457sFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(s) Flag", "terseLabel": "Rule 457(s)" } } }, "auth_ref": [ "r1177" ] }, "ffd_Rule457uFlg": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Rule457uFlg", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Rule 457(u) [Flag]", "terseLabel": "Rule 457(u)", "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due." } } }, "auth_ref": [ "r1178" ] }, "ffd_Scties424iAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Scties424iAxis", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Securities, 424I [Axis]", "terseLabel": "Securities, 424I" } } }, "auth_ref": [ "r1168" ] }, "ffd_Scties424iLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Scties424iLineItems", "lang": { "en-us": { "role": { "label": "Securities, 424I [Line Items]", "terseLabel": "Securities, 424I:" } } }, "auth_ref": [ "r1168" ] }, "ffd_Scties424iTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Scties424iTable", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/securities424iTable" ], "lang": { "en-us": { "role": { "label": "Securities, 424I [Table]", "terseLabel": "Securities, 424I Table" } } }, "auth_ref": [ "r1168" ] }, "ffd_Securities424iTableNa": { "xbrltype": "naItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "Securities424iNa", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Securities 424I [N/A]", "terseLabel": "Securities 424I N/A" } } }, "auth_ref": [] }, "ffd_SubmissionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "SubmissionLineItems", "lang": { "en-us": { "role": { "label": "Submission [Line Items]", "terseLabel": "Items" } } }, "auth_ref": [] }, "ffd_SubmissnTp": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "SubmissnTp", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/submissionTable" ], "lang": { "en-us": { "role": { "label": "Submission Type", "terseLabel": "Submission Type" } } }, "auth_ref": [] }, "ffd_TermntnCmpltnWdrwl": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TermntnCmpltnWdrwl", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable" ], "lang": { "en-us": { "role": { "label": "Termination / Completion / Withdrawal Statement", "terseLabel": "Termination / Withdrawal Statement" } } }, "auth_ref": [] }, "ffd_TtlFeeAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TtlFeeAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Total Fee Amount", "terseLabel": "Total Fee Amount" } } }, "auth_ref": [ "r1168" ] }, "ffd_TtlFeeAndIntrstAmt": { "xbrltype": "nonNegativeDecimal2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TtlFeeAndIntrstAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Total Fee and Interest Amount", "terseLabel": "Total Fee and Interest Amount" } } }, "auth_ref": [ "r1168" ] }, "ffd_TtlOfferingAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TtlOfferingAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Total Offering Amount", "terseLabel": "Total Offering" } } }, "auth_ref": [ "r1168" ] }, "ffd_TtlOffsetAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TtlOffsetAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Total Offset Amount", "terseLabel": "Total Offset Amount" } } }, "auth_ref": [ "r1168" ] }, "ffd_TtlPrevslyPdAmt": { "xbrltype": "nonNegative1TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TtlPrevslyPdAmt", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Total Previously Paid Amount", "terseLabel": "Previously Paid Amount" } } }, "auth_ref": [ "r1168" ] }, "ffd_TtlTxValtn": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TtlTxValtn", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable" ], "lang": { "en-us": { "role": { "label": "Total Transaction Valuation", "terseLabel": "Total Transaction Valuation" } } }, "auth_ref": [ "r1168" ] }, "ffd_TxValtn": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "TxValtn", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Transaction Valuation", "terseLabel": "Transaction Valuation" } } }, "auth_ref": [] }, "ffd_ValSctiesRcvd": { "xbrltype": "nonNegative100TMonetary2ItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "ValSctiesRcvd", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Value of Securities Received", "terseLabel": "Value of Securities Received", "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)" } } }, "auth_ref": [ "r1173" ] }, "ffd_ValSctiesRcvdPerShr": { "xbrltype": "nonNegativeDecimal4lItemType", "nsuri": "http://xbrl.sec.gov/ffd/2026", "localname": "ValSctiesRcvdPerShr", "presentation": [ "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable" ], "lang": { "en-us": { "role": { "label": "Value of Securities Received, Per Share", "terseLabel": "Value of Securities Received, Per Share", "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation." } } }, "auth_ref": [ "r1173" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-8" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482943/710-10-55-8" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-29" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(1)", "Publisher": "SEC" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(2)", "Publisher": "SEC" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480868/205-20-S45-2" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.Z.5.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-2" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-2" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-3" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-5" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-6" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-12" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2A" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-6" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-6" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-7" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-7" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-6" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480204/360-10-S45-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480125/505-10-S35-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-8" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SAB Topic 5.Q.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-7" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481468/505-20-05-5" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S25", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 1.D.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479921/505-20-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479279/805-10-65-5" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479279/805-10-65-5" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479279/805-10-65-5" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-7" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-7" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-7" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "45", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480865/815-45-50-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/825/tableOfContent" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482864/845-10-50-3" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 1.B.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480148/855-10-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480088/860-10-S50-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(cc)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-5" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "275", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479072/912-275-50-4" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-2" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(e)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(e)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.9-06)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478443/942-360-45-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "805", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477011/948-310-45-1" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2" }, "r986": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r987": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r988": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r989": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r990": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r991": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r992": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r993": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r999": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1000": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1001": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1002": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r1003": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r1004": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r1005": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1006": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1007": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r1008": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r1009": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1010": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1011": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1012": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r1013": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1014": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15" }, "r1015": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r1016": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20" }, "r1017": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r1018": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r1019": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12" }, "r1020": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1021": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11" }, "r1022": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14" }, "r1023": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18" }, "r1024": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21" }, "r1025": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24" }, "r1026": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4" }, "r1027": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1028": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r1029": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18" }, "r1030": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-3A" }, "r1031": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6" }, "r1032": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1033": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1034": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1035": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1036": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1037": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r1038": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r1039": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1040": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1041": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r1042": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-79" }, "r1043": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "80", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-80" }, "r1044": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r1045": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r1046": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r1047": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r1048": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r1049": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1050": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1051": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1052": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1053": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1054": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1055": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r1056": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1057": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1058": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "64", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64" }, "r1059": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1060": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1061": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1062": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1063": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1064": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1065": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1066": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1067": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1068": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1069": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1070": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1071": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1072": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r1073": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1074": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1075": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1076": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1077": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r1078": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1079": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8" }, "r1080": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39" }, "r1081": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41" }, "r1082": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43" }, "r1083": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47" }, "r1084": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1085": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1086": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1087": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1088": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1089": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1090": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1091": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1092": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1093": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29" }, "r1094": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29" }, "r1095": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1096": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1097": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1098": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1099": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1100": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1101": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1102": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1103": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1104": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1105": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1106": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1107": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1108": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1109": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1110": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1111": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13" }, "r1112": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1113": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "181", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181" }, "r1114": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r1115": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1116": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1117": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1118": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1119": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1120": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1121": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1122": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10" }, "r1123": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12" }, "r1124": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1125": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1126": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r1127": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r1128": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r1129": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-4" }, "r1130": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-5" }, "r1131": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r1132": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r1133": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "845", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482819/845-10-05-6" }, "r1134": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1135": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "108", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481296/860-20-55-108" }, "r1136": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-2" }, "r1137": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1138": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1139": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1140": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1141": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1142": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1143": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1144": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1145": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1146": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1147": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1148": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1149": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1150": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1151": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1152": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11" }, "r1153": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14" }, "r1154": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1155": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1156": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1157": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1158": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1159": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1160": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1161": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1162": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1163": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478790/946-405-45-2" }, "r1164": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1165": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1166": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1167": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1168": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230" }, "r1169": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "415", "Subsection": "a" }, "r1170": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "429" }, "r1171": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457" }, "r1172": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457", "Subsection": "b" }, "r1173": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457", "Subsection": "f" }, "r1174": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457", "Subsection": "o" }, "r1175": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457", "Subsection": "p" }, "r1176": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457", "Subsection": "r" }, "r1177": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457", "Subsection": "s" }, "r1178": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "457", "Subsection": "u" }, "r1179": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Subsection": "f", "Section": "457" }, "r1180": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r1181": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org/705/tableOfContent" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph": "a", "Publisher": "SEC" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-3" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(r)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(s)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(t)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(u)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-3" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482558/350-40-50-1" }, "r1335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482222/360-10-30-2" }, "r1336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3" }, "r1337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r1338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r1339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r1340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r1341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r1342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r1343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2" }, "r1358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r1362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r1364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2" }, "r1365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3" }, "r1366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1" }, "r1367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-2" }, "r1368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r1369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r1370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-2" }, "r1371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-2" }, "r1372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r1422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r1424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r1433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r1434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4" }, "r1461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r1462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r1469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r1470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r1477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r1479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r1481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "15", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481116/815-15-25-1" }, "r1485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "15", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481116/815-15-25-4" }, "r1486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r1487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2C" }, "r1500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2D" }, "r1501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r1505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r1506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r1507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r1508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13" }, "r1509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r1523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-8" }, "r1524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-8" }, "r1525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-2" }, "r1526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "905", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478704/905-360-25-4" }, "r1527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478482/942-210-50-1" }, "r1529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1" }, "r1530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1" }, "r1531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.9-06)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r1539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "810", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477383/970-810-45-1" }, "r1595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1" }, "r1596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1" }, "r1597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-1" } } }